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1.  Executive Summary  
1.1 Summary findings 
 
1.1.1 In tackling the problem of Alcohol Related Brain Damage (ARBD) and working 
through the maze of all syndromes with wider diagnostic, treatment, legal, 
commissioning and funding issues, evidence from specialist ARBD services 
have begun to highlight that with clinically validated assessment tools, early 
identification of ARBD, with pharmacological, psychosocial interventions and 
having a rehabilitative model, ARBD – contrary to the popular myth – is a non-
progressive condition. 
 
1.1.2 Under-diagnosis of ARBD is an acknowledged issue not only within clinical 
settings, but also in the community. Failure to present at services, for reasons 
including stigma, is common. Patients may usually first become visible to 
services when they are assessed at home or in general hospital settings and 
rarely through direct referral to psychiatric services, where their needs might 
be more quickly identified.   
1.1.3 High quality awareness, education and training around ARBD among health 
and social care staff is required to combat lack of knowledge and inimical 
attitudes, and to improve early identification, diagnosis and service quality.    
1.1.4 In hospital and secondary care settings, patients with ARBD may present with 
cognitive damage due to a host of syndromes and it becomes important to 
differentiate these conditions with an emphasis on prevention of the more 
severe ARBD syndromes such as Wernicke-Korsakoff’s syndrome.  
Therefore, safely managing an acute alcohol withdrawal as per NICE 
guidelines, use of Pabrinex® both for treating a suspected Wernicke-
Korsakoff’s syndrome and as a prophylactic treatment for high-risk individuals 
becomes imperative. 
1.1.5 Neuropsychological testing offers an effective and relatively inexpensive 
method of ARBD diagnosis and provides a wealth of information regarding 
each person’s symptomology in a frequently varied condition. However, 
neuropsychological test outcomes alone provide insufficient evidence for 
making ARBD diagnoses due to the multiple possible causes of impaired 
performance on such tests (e.g., head injuries, neurodegenerative diseases, 
poor pre-morbid functioning etc.). As a result, all neuropsychological test 
outcomes need to be considered in conjunction with a clinical diagnostic 





1.1.6 Few dedicated services currently exist across the UK for the management of 
ARBD and, as a result, patients may be placed within a range of different 
service types such as adult mental health services, memory services and 
alcohol treatment services. Alcohol services may meet some of their needs 
but struggle to engage those with cognitive impairment. Older adult mental 
health services can provide longer term care for those with permanent 
cognitive impairment but many people with ARBD are younger than their 
threshold age (often 65) and these services generally do not have the 
expertise to deal with alcohol misuse (McCabe, 2006). As a result, patients 
can find themselves placed between services with disagreement over which 




Awareness raising, education and training 
1.2.1 Development of a co-ordinated national awareness raising campaign for 
public, patients, families and carers – multi-media (radio, social media, 
television and print) regarding the potential risks of heavy and prolonged use 
of alcohol and where to seek support/referral. 
1.2.2 Development and evaluation of targeted and appropriate Patient Information 
Leaflets (PILs) to patients, families and carers to promote health choices. 
1.2.3 Development of a three tier nationally accredited (AGORED, RCGP and 
Deanery) education and training programme on alcohol, detoxification and 
alcohol-related brain damage: 
a. Tier 1 – Basic training providing an overview of ARBD for all professionals 
who may work with individuals with, or at risk of, ARBD. Focus on early 
identification. 
b. Tier 2 - More detailed and comprehensive training including symptoms 
and screening tools and protocols for those likely to work directly and 
regularly with ARBD (e.g., addictions psychiatrists/ psychologists, 
substance misuse social workers). 
c. Tier 3 - Specialist assessment, diagnosis and management of ARBD for 
clinical and non-clinical specialists and those providing Tiers 1 and 2 
training. 
Prevention, assertive outreach and early identification  
1.2.4 Those who use alcohol should be informed that their consumption decisions 




ARBD, and that effects of alcohol can become apparent at what are regarded 
as “safe” levels of consumption.  
1.2.5 In line with the National Institute for Health and Care Excellence (NICE), the 
Royal College of Physicians and the British Association for 
Psychopharmacology recommendations, parenteral Pabrinex® and oral 
Thiamine should be prescribed, including under a PGD, for all individuals with 
heavy and/or prolonged drinking patterns, identified with or at risk of ARBD. 
1.2.6 Surveillance and trials that are able to record variations in cognitive 
performance in respect of alcohol use, and what, if any, pharmacologic or 
dietary measures ameliorate decline are required. 
1.2.7 All alcohol detoxifications should be undertaken in line with NICE clinical 
guidance and as part of a planned care pathway, in conjunction with local 
addiction specialist services and recorded on the patient management system 
within the clinical alcohol services.  
1.2.8 Cognitive screening of individuals with a history of significant alcohol use 
should be routine (on at least a quarterly basis if alcohol consumption 
continues) in clinical and community-based settings to identify those with/at 
risk of ARBD.  
1.2.9 Area Planning Boards should consider commissioning assertive outreach 
services for patients with ARBD, particularly those who are homeless. 
Clinical care pathway 
1.2.10 Establishment of dedicated ARBD Services within each Health Board, with 
ARBD clinical specialist, clinical psychologist, occupational therapist, social 
services and general medicine and timely access to appropriate evidence 
based diagnostic tools.  
1.2.11 Establishment of regional inpatient centres of excellence for ARBD to support 
appropriate diagnostic assessment, research and evaluation on clinical and 
service delivery models. 
1.2.12 Social care services consider a comprehensive accommodation provision, not 
requiring abstinence from alcohol as a prerequisite. 
Maintaining and validating quality standard and service improvement  
1.2.13 Support a comprehensive and co-ordinated programme of evaluation including 
validation of ARBD screening and diagnostic tools, rehabilitative models of 




1.2.14 Support prevalence and incidence studies evidencing the nature and scale of 
ARBD and at risk populations within Wales, including within Prison services to 










2.1 Purpose and structure 
2.1.1 This document is designed to inform and assist health and social care 
planners and providers to design and deliver quality, sustainable and equitable 
prevention and treatment services for those at risk of ARBD.   
2.1.2 The intended audience includes service planners, commissioners, substance 
misuse and wider health and social care providers working with current or pre-
existing problematic alcohol use.   
2.1.3 The document provides an overview of the existing situation in Wales and the 
wider UK and outlines the evidence to inform improvements.  Links to relevant 
strategy and policy documents are provided along with a summary of the 
evidence relating to required development of services aimed at improving the 
health and wellbeing of individuals with or at risk of developing ARBD.  
2.1.4 This guidance document forms part of the suite of harm reduction and 
Substance Misuse Treatment Framework (SMTF) guidance for those working 
in Wales available at: Welsh Government Substance Misuse website 
2.2   Strategic context 
2.2.1  Following increased concern and publication of a number of key documents 
that have recently been published, including Alcohol Change UK’s ‘All in the 
Mind’, Royal College of Psychiatrists (RCPsych) ‘CR185 report’ and Public 
Health Wales (PHW) ‘Evidence – based profile of alcohol related brain 
damage in Wales’,  
2.2.2  As a consequence of publications and highlighting the issue in Wales, the 
Welsh Government Substance Misuse Delivery Plan 2016-181 and latest 
Substance Misuse Delivery Plan 2019-222, outlined specific actions to raise 
awareness, improve training, education and diagnosis and establish clear 
pathways for referral and treatment see Section 3.  
2.3   Methodology  
2.3.1  To oversee development of the SMTF for ARBD a Project Board was 
established in 2015 and from the Project Board membership, the ARBD 
working group was developed to draft the SMTF to publication. 
                                                          
1 Available at: Substance Misuse Delivery Plan 2016-2018 




2.3.2 The evidence within this document is drawn from a range of sources including 
bibliographic databases, personal communication with leading ARBD 
academics, evidence gathering events and key informant interviews. The 
databases and website sources included MEDLINE, MEDLINE Daily Update, 
AMED, BNI and EMBASE. Websites included NICE, Health Protection 
Agency, Welsh Government, Department of Health. 
2.4 Roles and responsibilities 
2.4.1 Welsh Government, Health Boards, criminal justice, local authorities and third 
sector organisations will be responsible for ensuring delivery of the SMTF for 
ARBD. Multi-disciplinary ARBD working groups should develop an action plan 
focusing on areas for development within and across services.  
2.5 Definition and key issues 
2.5.1 ARBD is an umbrella term used to describe a spectrum of conditions 
characterised by chronic cognitive impairment due to changes in the structure 
and function of the brain attributed to excessive alcohol consumption over 
time. See Figure 1.   
2.5.2 One of the most well-known and severe types of ARBD is Wernicke-
Korsakoff’s Syndrome (WKS), a two phase disorder that proceeds from 
Wernicke’s Encephalopathy (WE) on to Korsakoff’s Syndrome (KS). WE is an 
acute neuropsychiatric condition that is characterised by confusion, cerebellar 
ataxia and oculomotor dysfunction (ophthalmalgia, nystagmus); though is also 
frequently associated with peripheral neuropathy, disorientation and the onset 
of a coma (Caine et al., 1997). The second phase, KS, is a prolonged disorder 
characterised by a profound memory deficit (anterograde amnesia) and milder 
impairments in executive function (including poor planning and decision-
making capabilities), visuospatial processing and attention (Heirene, John, 





Figure 1 – Alcohol related brain damage, adapted from Wilson et al (2015). 
2.5.3 WKS is believed to be caused by thiamine (vitamin B1) deficiency and, as a 
result, can occur in anyone prone to vitamin deficiencies (e.g., those with 
eating disorders). However, in contemporary Western societies, WKS is 
primarily seen in those with alcohol dependence due to their poor nutritional 
intake and the disruptive effects of alcohol on the absorption and metabolism 
of thiamine.  
2.5.4      Despite including a diverse range of conditions, ARBD has proven a useful 
way to define a category of patients with common social and clinical needs 
and similar prospects for rehabilitation.   
2.5.5 Evidence from specialist ARBD services has begun to highlight that, with 
clinically validated assessment tools, early identification of ARBD with 
pharmacological, psychosocial interventions and having a rehabilitative model: 
 
 ARBD is a non-progressive condition provided abstinence is achieved. 
 Acute hospital bed day usage can be reduced by up to 85%. 
 Quality of life can be dramatically improved in individuals, with as high as 
75% of them being cared and managed in non-institutional community 
settings (Wilson et al., 2012). 
 
        ARBD is not a degenerative condition if the patient stops drinking. It has 
been estimated that up to 75% can achieve some degree of recovery with 
appropriate rehabilitative support. 
2.5.6 Under-diagnosis of ARBD is an acknowledged issue not only within clinical 
settings, but also in the community. Failure to present at services, for reasons 
including stigma, is common. Patients usually first become visible to services 




through direct referral to psychiatric services, where their needs might be 
more quickly identified.   
2.5.7 The progression of WE into KS may be halted if treated early with parental 
thiamine and appropriate management of withdrawal. Yet, approximately 56-
85% of patients with WE go on to develop KS (Cook et al., 1998; Wood et al., 
1986), significantly reducing the likelihood of their full recovery. Thus, early 
recognition and timely intervention is vital to improve prognoses.  
2.5.8 In hospital and secondary care settings, patients with ARBD may present with 
cognitive damage due to a host of syndromes, as outlined in Table 1 below, 
and it becomes important to differentiate these conditions with an emphasis on 
prevention of the more severe ARBD syndromes such as WKS.  Therefore, 
safely managing an acute alcohol withdrawal as per NICE guidelines, use of 
Pabrinex® both for treating a suspected WKS and as a prophylactic for high 
risk individuals, becomes imperative.   
Table 1. Alcohol Related Brain Damage Syndromes  
(David et al., 2009; Kopelman, 1991). 
NEUROLOGICAL NEUROPSYCHIATRIC 
 
- Acute/Chronic Dysarthrias 
and/or ataxia 
- Seizures- withdrawals, 
hypoglycaemia, trauma & 
precipitation of epilepsy 
- Peripheral Neuropathy 
- Degenerative Syndromes- 
corpus callosum, central 
pontine myelinolysis, 




- Acute withdrawals & Delirium 
Tremens 
- Alcoholic hallucinosis 
- Alcoholic Blackouts 
- Wernicke’s Encephalopathy 
- Hepatic Encephalopathy 
- Pellagra Encephalopathy 
Chronic 
- Coarsening of personality- 
frontal lobe atrophy 
- Korsakoff’s Syndrome 






2.5.9 Multiple issues around presentation to clinical services and diagnosis can lead 
to cases being missed, undiagnosed or misdiagnosed including:  
 The requirement for a period of abstinence prior to diagnosis. 
 Lack of appropriate guidelines, education and training (or guidelines not put 
into practice) across services including psychiatric inpatient wards, GP 
practices and Emergency Departments. 
 Overlap with non-alcohol related conditions such as other dementias. 
 Variable or incomplete clinical signs. 
 The broad spectrum of damage associated with ARBD.  
 The possibility that standard brief cognitive assessment tools may miss less 
severe damage.   
 Historical lack of specific diagnostic/assessment tools – or agreement of 
suite of assessment tools. 




 3. Education, awareness raising, training and workforce 
development 
3.1 Background 
3.1.1 A report exploring the care of those with ARBD in North Wales found that 
those with the condition may have stopped drinking sooner had they known 
that the brain damage caused could be improved by abstinence (Boughy, 
2007). 
3.1.2 A lack of knowledge and understanding of ARBD among nursing and medical 
staff in the UK has been repeatedly highlighted as a barrier to improving the 
care and support of those with the condition (Boughy, 2007; Heirene et al., 
2018b; Wilson, 2011). 
3.1.3 Poor knowledge of ARBD is problematic as the acute symptoms of WE are 
often confused with those of intoxication particularly within Emergency 
Departments (Sechi & Serra, 2007) or missed altogether (Harper, Giles, & 
Finlay-Jones, 1986), resulting in a failure to intervene at a time when the 
condition’s prognosis could be greatly improved by intervention.  
3.1.4 The lack of knowledge surrounding ARBD is further complicated by the 
stigmatisation and marginalisation of this group, which is likely to be even 
greater than that of individuals with substance misuse disorders without brain 
damage.  
3.1.5 Beliefs may exist around personal responsibility, for example, “… they brought 
the problem [alcoholism] on themselves” and that they do not “deserve” 
treatment (Svanberg, Morrison, & Cullen, 2015).   
3.1.6 Those with ARBD may be perceived as “unmotivated” or “unwilling” to engage 
with services due to damage to the areas of their brain responsible for 
motivation and behaviour change (Beaunieux, Eustache, & Pitel, 2015). This 
may in turn lead to what has been termed “therapeutic nihilism”, in which 
clinicians feel unable to effect meaningful change (Svanberg et al., 2015).   
3.1.7 Other changes to the areas of the brain responsible for behavioural control 
can result in impulsive and/or aggressive behaviour (Beaunieux et al., 2015), 







3.2  Evidence 
 
3.2.1  Education and awareness raising in the public 
3.2.1.1 Awareness raising in the general population is required to support the 
prevention and identification of at-risk individuals, to promote early 
engagement, diagnosis and treatment (RCP, 2014; Emmerson and Smith, 
2015).  
3.2.1.2 The RCP (2014) provide a brief patient and public information leaflet3 
providing an outline of what ARBD is, how it is caused and what treatment 
options are available. Similarly, Alcohol Change UK offer a range of ‘fact-
sheets’ relating to ARBD, and these can be found on the charity’s website.4  
3.2.1.3 The wide-spread dissemination of information via leaflets and other forms of 
mass and multi-media such as radio, TV soap opera story line campaigns may 
increase public awareness and understanding of ARBD, potentially decreasing 
the stigma faced by this population and increasing early recognition.  
3.2.1.4 Randomised clinical trials suggest that providing PILs in clinical settings can 
have a number of benefits, including increased patient knowledge and 
satisfaction and greater adherence to treatment, diet and lifestyle advice 
(Sustersic et al., 2017).  
3.2.1.5 Research has highlighted a number of factors that can improve the 
effectiveness of PILs, including, for example, the inclusion of pictures or 
pictograms (Colledge et al., 2008). Sustersic and colleagues (2017) provide a 
checklist to ensure the quality of PILs based on the best available evidence to 
date. This checklist includes items related to the content (e.g., based on the 
latest evidence-based medicine) and design (e.g., simple syntax and 
vocabulary) of PILs. The benefits of PILs may be augmented by using the 
“Teach back” method in which the patient is asked to “teach” it to their clinician 
after having read it at home or earlier in the session. Employing this method 
can identify those who may have poor health literacy and have struggled to 
assimilate the information provided (Colledge et al., 2008). 
                                                          
3 Royal College of Psychiatrists Alcohol Related Brain Damage patient and public 
information leaflet 2014.  Available at: Royal College of Psychiatrists Alcohol Related 
Brain Damage patient and public information leaflet 
 
4 Alcohol Concern Fact Sheet ‘Alcohol Related Brain Damage – what is it?’  Available 





3.2.1.6   Colledge et al. (2008) have recommended that in addition to PILs, health 
information can be disseminated in a variety of other formats, including audio 
recordings, websites and videos. Evidence suggests these methods may be 
equally or more effective ways of delivering health-related information (Suggs, 
2006), although fewer rigorous evaluations of their accuracy are available. 
3.2.1.7   A 2010 review of mass media campaigns aimed at changing health behaviour 
suggested a number of factors can improve their effectiveness (Wakefield, 
Loken & Hornik, 2010): 
 
 All campaign messages should result from sound research of the 
target group (e.g., alcohol users and their families) and be piloted 
with them. 
 Behaviour is most likely to be influenced if campaign messages are 
delivered in areas where the requisite services are available to 
support people with the condition/behaviour. 
 Sufficient funding must be available to ensure frequent and 
widespread exposure of campaign messages.   
 
 
3.2.2  Education, awareness raising and training for patients, families and 
carers 
3.2.2.1 To date, no research has investigated awareness raising strategies for ARBD, 
but the same strategies used for augmenting public awareness (e.g., PILs and 
public media campaigns) may be applicable to this group.  
3.2.2.2   Alcohol Change UK offer a specific fact-sheet providing guidance on caring for 
someone with the condition for the families and carers of someone with 
ARBD.5 They also provide three legal factsheets covering decision making, 
lasting power of attorney and the Mental Capacity Act, which may be 
particularly useful for those families and carers. Again, education and 
awareness in this population could also be achieved through the other more 
general leaflets and factsheets discussed above. 6 
                                                          
5   Alcohol Change UK ‘Alcohol-Related Brain Damage - Road to Recovery: A handbook 
for the families, carers and friends of people with Alcohol Related Brain Damage.’  
Available at: Alcohol Change UK Alcohol Related Brain Damage Road to Recovery 
handbook  




3.2.2.3   Specific training courses for families and carers could also be of significant 
value. Alcohol Change UK state that they cover this area to some extent in 
their training programme, although no specific courses are known to the 
authors. 
 
3.2.3  Education, awareness raising and training for health and social care 
professionals 
3.2.3.1 High quality awareness, education and training around ARBD among health 
and social care staff is required to combat lack of knowledge and inimical 
attitudes, and to improve early identification, diagnosis and service quality    
3.2.3.2 At present, there is a dearth of evidence outlining or evaluating training and 
education programmes on ARBD. The lack of available training has been 
highlighted as a significant barrier to improving ARBD service provision in 
Wales.   
3.2.3.3   Introductory courses are currently available via Alcohol Change UK and 
NewLink Wales.  The Royal College of General Practitioners (RCGP) also 
offer a certificate in Management of Alcohol in primary care now offer a one-
day introductory course available across the UK.  
3.2.3.4 Thomson et al. (2012) have suggested the NICE (2010a, b, 2011) guidance 
on alcohol-use disorders can be used to structure training and increase the 
identification of alcohol-related harms. These guidelines have, however, been 
criticised for a lack of specification regarding thiamine administration and 
dosing recommendations (Bell, 2012), highlighting the need to also consult up-
to-date empirical evidence to inform ARBD training.  
3.3 Recommendations 
3.3.1 Development of a co-ordinated national awareness raising campaign for 
public, patients, families and carers – multi-media (radio, social media, 
television and print) regarding the potential risks of heavy and prolonged use 
of alcohol and where to seek support/referral. 
 
3.3.2 Development and evaluation of targeted and appropriate PILs to patients, 
families and carers to promote health choices. 
 
3.3.3 Development of a three tier nationally accredited (AGORED, RCGP and 





a. Tier 1 – Basic training providing an overview of ARBD for all 
professionals who may work with individuals with, or at risk of, 
ARBD. Focus on early identification. 
b. Tier 2 - More detailed and comprehensive training including 
symptoms and screening tools and protocols for those likely to work 
directly and regularly with ARBD (e.g., addictions psychiatrists/ 
psychologists, substance misuse social workers). 
c. Tier 3 - Specialist assessment, diagnosis and management of 
ARBD for clinical and non-clinical specialists and those providing 





4.  Prevention of Alcohol Related Brain Damage amongst high 
risk populations 
4.1 Background     
4.1.1 It is becoming increasingly clear that there is an association between alcohol 
consumption and structural and functional abnormalities of the brain that are in 
turn associated with cognitive decline, and at levels of consumption within 
current recommended safe levels [Topiwala et al., 2017; Puimatti et al, 2018). 
However, cognitive deficits are most apparent in those who are chronic or 
dependant users of alcohol (e.g. Wernicke-Korsakoff Syndrome) (Sechi & 
Serra, 2007; Harper, 2009), brain weight is reduced in dependant alcohol 
users (Harper & Blumbergs, 1982) and the extent of atrophy is associated with 
lifetime consumption of alcohol measures (Harding et al, 1996).  
4.1.2 One putative mechanism linking alcohol consumption with structural and 
functional abnormalities of the brain concerns the metabolism of thiamine 
hydrochloride. In those who use alcohol to excess, thiamine deficiency can 
emerge due to self-neglect, inadequate diet, the decreased transport of 
thiamine across intestinal mucosa, the low capacity of the liver to store the 
vitamin, and the impaired conversion of thiamine to the active compound 
thiamine pyrophosphate, a derivative of thiamine that is essential to the proper 
function of the nervous system (Sechi & Serra, 2007; Hoyumpa, 1980; 
Thomson, 2000).  
4.1.3 Genetic and environmental factors may also contribute, as can magnesium 
deficiency (Sechi & Serra, 2007). If alcohol-related abnormalities are a 
consequence of alcohol disrupting the availability of thiamine, then such 
abnormalities can be prevented or treated through replenishing levels of 
thiamine. NICE, the Royal college of Physicians and the British Association for 
Psychopharmacology (NICE, 2010; NICE, 2011; Thomson et al, 2002; 
Lingford-Hughes et al, 2012) all recommend parenteral high dose thiamine as 
a prophylactic for those at risk of WKS.  
4.1.4 According to guidelines (NICE, 2010; NICE, 2011; Thomson et al, 2002; 
Lingford-Hughes et al, 2012), patients undergoing acute alcohol withdrawal 
should be treated with benzodiazepine or carbamazepine. In people with 
delirium tremens, oral lorazepam may be offered as first-line treatment and 
parenteral lorazepam, haloperidol or olanzapine if symptoms persist. Oral or 
parenteral thiamine should be offered to those with suspected or are at 
elevated risk of developing WE. Dose is at the upper end of the British 




4.2 Evidence   
4.2.1 WE results from an acute deficiency of thiamine while KS is a chronic 
neurologic consequence of WE. There has been one Cochrane Review on the 
use of thiamine as a treatment for WKS (Day et al, 2013). The review covered 
all “randomized trials in which treatment with thiamine or thiamine-containing 
products was administered and compared with alternative interventions for 
people with, or at risk of developing, WKS secondary to alcohol abuse.” Two 
studies were identified, only one (Ambrose et al, 2001) of which was suitable 
for inclusion but contained methodological shortcomings.  
4.2.2 A more general and recent review on treatments for ARBD and the 
subcategory WKS was published in 2013 (Ambrose et al, 2001). This review 
found tentative evidence to support guidance for rehabilitation, although 
highlighted weak methods in the available research literature and the review 
was further limited by a small number of relevant studies. None of the studies 
included in the review considered high-dose IV thiamine as an intervention, 
being mostly cross-sectional (e.g. patients with KS vs. controls) and focused 
mostly on forms of cognitive rehabilitation. Outcomes were mostly concerned 
with aspects of memory access and related executive function. 
4.2.3 Whilst one extreme of ARBD is the classical presentation of WKS, the other 
milder or the less obvious form more frequently seen in clinical settings is the 
frontal lobe dysfunction.  The majority of these people present with cognitive 
damage as a result of the direct toxic effects of alcohol and vitamin 
deficiencies from secondary neuropsychiatric conditions.  WKS is a reversible 
and treatable condition in its early stages of onset.   It therefore follows that 
one of the simplest and most obvious methods of preventing ARBD is 
reducing the total alcohol consumption in the population and supplementing 
Vitamin B 1 at a local and population level.  
4.2.4 In addition to the concerns surrounding thiamine depletion, a number of 
studies have identified associations between depletions of other vitamins and 
minerals and alcohol-related neurological complications. For example, low 
levels of zinc have been associated with an increased likelihood of 
experiencing delirium tremens and prolonged hallucinations during withdrawal 
(Bogden & Troiano, 1978), and deficiencies in other B vitamins such as niacin 
(B3) and pyridoxine (B6) are known to underpin various neurological disorders 
associated with alcohol misuse (i.e., Pellagra and alcoholic seizures, 
respectively; Cook, Hallwood, & Thomson, 1998). Moreover, subclinical 
deficiencies of vitamins A, C, D and E have all been observed and tentatively 
implicated as contributors to the neurocognitive impairment experienced by 
alcohol dependent individuals (Bogden & Troiano, 1978; Cook et al., 1991). 




ARBD may be particularly important due to the vitamin’s crucial role in the 
conversion of thiamine to its neurologically useable state: thiamine 
pyrophosphate (Sechi & Serra, 2007). Thus, a severe magnesium deficiency 
may result in refractory WKS if left untreated (Traviesa, 1974).  When 
completing blood test for alcohol use disorder patient, including Magnesium 
routinely under urea and electrolyte (U&Es) blood test requests is required.  
Depending on levels, supplement Magnesium should be provided.   
4.3 Recommendations  
 
4.3.1 Those who use alcohol should be informed that their consumption decisions 
will have significant bearing on their risk of experiencing cognitive decline and 
ARBD, and that effects of alcohol can become apparent at what are regarded 
as “safe” levels of consumption.  
 
4.3.2 In line with NICE, the Royal College of Physicians and the British Association 
for Psychopharmacology recommendations, parenteral and oral thiamine 
should be prescribed, including under a PGD, for all individuals with heavy 
and/or prolonged drinking patterns, identified with or at risk of ARBD. 
4.3.3. Surveillance and trials that are able to record variations in cognitive 
performance in respect of alcohol use, and what, if any, pharmacologic or 




5. Early identification 
5.1  Background 
5.1.1 The early identification and diagnosis of ARBD can significantly improve 
subsequent treatment outcomes. The symptoms of WE, for example, can be 
largely relieved via treatment with parenteral thiamine if recognised early (Day 
et al., 2013).   
5.1.2 The historical under-diagnosis of ARBD (see also: Harper, 1983; Harper, 
Giles, & Finlay-Jones, 1986) has been attributed to the lack of training, stigma 
surrounding those with substance abuse problems, and the challenge of 
differentiating between the similar presentations of WE and intoxication (Sechi 
& Serra, 2007; Thomson, Guerrini, Bell, et al., 2012).  
5.1.3 Early identification is further complicated by the heterogenous presentation of 
ARBD (Bowden, 1990) and the frequent comorbidities (e.g., depression, 
unspecified encephalopathy etc.) that accompany the condition (Wilson et al., 
2012).  
5.1.4 Due to the nature of the cognitive impairment in ARBD and lack of awareness 
of the condition among some clinical staff, many patients are not picked up by 
clinical services until they experience significant cognitive impairment 
(ARBIAS, 2009). Memory loss is easily recognised by family and friends but 
frontal lobe dysfunction, which is frequently the initial feature of ARBD, may 
not be recognised as the characteristic dysexecutive syndrome and may be 
incorrectly labelled as a lack of motivation and disorganisation secondary to 
intoxication (Cummings, 2005; Schmidt et al., 2005). 
5.1.5 Despite the challenges currently facing the early identification of ARBD, a 
number of methods are available for screening and diagnostic purposes. 
Neuropsychological (or cognitive) assessment has been proposed as the most 
reliable method of diagnosing ARBD (Hayes, Demirkol, Ridley, Withall, & 
Draper, 2016), with a focus on tests of memory and executive functioning. 
However, several other modes of assessment can also provide clinically 
valuable information about a person’s condition and should also be 
considered. These include neuroimaging investigations, nutritional status 
evaluations and assessments of activities of daily living (Horton, Duffy, Hollins 







5.2  Evidence 
 
5.2.1    Early signs and symptoms 
5.2.1.1 Given the severity of WE and its poor prognosis if left untreated (historically a 
20% fatality rate; Harper et al., 1986), familiarity with the early signs of 
thiamine deficiency can play an important role in early identification. 
Accordingly, the clinical indicators of early and late-stage thiamine deficiency 
outlined by Thomson, Guerrini, and Marshall (2012) are presented below (see 
Appendix A for other ARBD diagnostic criteria as preliminary guides for 
identification and diagnosis).   
Table 2 – Signs and symptoms of thiamine deficiency / Wernicke-Korsakoffs 















5.2.1.2   Other signs and symptoms of ARBD that have been observed in the literature 
include deficits in long-term memory for experiences (i.e., episodic memory), 
particularly after the onset of the condition (i.e., anterograde amnesia), 
impairments of higher-order cognitive skills such as decision making and 
planning, and behavioural symptoms such as aggression, impulsivity and 
frequent attendances at hospital (RCP, 2014; Wilson et al., 2012). 
Signs and symptoms of thiamine deficiency/WKS  
Early signs and symptoms: 
 Loss of appetite 
 Nausea/ vomiting 
 Fatigue, weakness, apathy 
 Giddiness, diplopia 
 Insomnia, anxiety, difficulty in concentration 
 Memory loss 
Later signs and symptoms: 
 Classic triad: oculomotor abnormalities, cerebellar dysfunction 
(ataxia) and confusion 
 Quiet global confusion with disorientation in time/ place 
 Confabulation/ hallucination 
 Onset of coma 
Operational criteria for Wernicke’s Encephalopathy (Caine et al., 1997): 2 
of the following: 
 Dietary deficiencies 
 Oculomotor abnormalities 
 Cerebellar dysfunction 




5.2.1.3 Identification of patients with potential ARBD on acute inpatient wards requires 
a pragmatic approach. The Wirral service has adopted a two-phase process 
whereby high-risk patients are initially identified by ward nurses or alcohol 
liaison nurses using general information from the clinical history and then a 
more specialist assessment is provided by the ARBD team consultant within 
five working days. This process is suitable for more acutely unwell patients 
presenting in the acute hospital setting. 
5.2.2  Operational criteria for possible ARBD diagnosis 
5.2.2.1   Wilson and colleagues (2012) have propounded operational criteria for ARBD 
for use by nurses in acute hospital settings. These criteria are yet to be 
validated, but could assist in the early identification of those with or at risk of 
ARBD. If all three of the following criteria are met then referral to specialist 
ARBD services should be made (see Appendix A for other ARBD diagnostic 
criteria): 
 
a. Probable drinking history of heavy, long-standing alcohol drinking: 35 units or 
more a week for at least five years.  
b. Confusion, memory problems, doubt about capacity and concerns about risk 
on discharge, after withdrawal/ physical stabilisation. 
c. Three or more admissions into hospital and/or Emergency Department in 12 
months probably associated either directly (withdrawal, unconscious) or 
indirectly (trauma organ diseases, etc.) with alcohol ingestion or one or more 
delayed discharges from general hospital wards in the last 12 months (a 
delayed discharge is defined as patients staying on the acute medical/ 
surgical ward because of social and/ or psychiatric problems). 
 
5.2.3  Cognitive Screening 
5.2.3.1 Cognitive Screening Instruments (CSIs) are brief tests of cognition that offer 
an insight into an individual’s level of functioning in a variety of areas (e.g., 
memory, attention etc.). Cognitive screening can be undertaken in a variety of 
environments (e.g., treatment centres, bedside) by different professionals 
(e.g., nursing staff, social workers) with little training required, thereby 
increasing the chances of early identification. A summary of the findings 
relating to CSIs from Heirene and colleagues’ (2018a) recent systematic 
review of neuropsychological tests used for ARBD assessment is presented 
below (for a tabulated overview of findings relating to the utility of various CSIs 
in this domain, see Appendix C). 
5.2.3.2   Both the MoCA (Nasreddine et al., 2005) and MMSE (Folstein, Folstein, & 
McHugh, 1975) are effective at distinguishing between those with and without 




cut-off point for impairment is adjusted accordingly), though the MoCA 
appears the superior of the two (Oudman et al., 2014; Wester, Westhoff, 
Kessels, & Egger, 2013).  
5.2.3.3   The ACE-III (Hsieh, Schubert, Hoon, Mioshi, & Hodges, 2013) also appears 
useful as a screening tool for ARBD and provides a more comprehensive 
overview of cognition while remaining quick to administer (Brown, Heirene, 
Roderique-Davies, John, & Evans, 2019). The ACE-III is the most frequently 
used cognitive screening instrument in South Wales for ARBD diagnosis 
(Heirene et al., 2018b; see Appendix C for the average ACE-III scores for 
alcohol-dependent individuals with and without ARBD). 
5.2.3.4 Two new CSIs have recently been developed specifically for assessing 
alcohol-related cognitive impairments: the Brief Examination of Alcohol-
Related Neuropsychological Impairments (BEARNI; Ritz et al., 2015) and the 
Test of Detection of Cognitive Impairment in Alcoholism (TEDCA; Jurado-
Barba et al., 2017), although both have only been validated in alcohol 
dependent populations not meeting ARBD criteria (both CSIs can be accessed 
in the corresponding publications (the BEARNI is currently only available in 
French). Nonetheless, both have shown sensitivity to mild alcohol-related 
cognitive deficits in their validation and are more focused on the functions 
particularly vulnerable to alcohol abuse: memory, executive function and 
visuospatial processing. These tests do not appear to have been adopted in 
UK practice as of yet (Heirene et al., 2018b) 
5.3  Recommendations 
5.3.1 Cognitive screening, by competent health practitioners, of individuals with a 
history of significant alcohol use should be routine (on at least a quarterly 
basis if alcohol consumption continues) in clinical and community-based 
settings to identify those with/at risk of ARBD.  
 
5.3.2 Area Planning Boards should consider commissioning assertive outreach 




6. Assessment and diagnosis 
6.1 Background 
6.1.1 Following screening and initial identification of those displaying signs of 
ARBD, it is important to undertake more detailed and comprehensive 
assessments in order to clarify the diagnosis and to exclude other pathologies 
(e.g., dementias). The most consistent and prominent brain changes in those 
with ARBD include an increase in cerebrospinal fluid volume, widespread grey 
matter volume decreases (particularly in the frontal lobes), and reductions in 
the volume of the corpus callosum, cerebellum, pons, mamillary bodies, 
hippocampus and thalamus (Harper, 2009; Zahr et al., 2011). Most of these 
structural changes are thought to occur along a spectrum, with KS at the 
severe end of brain damage (Zahr et al., 2011). 
6.1.2 Modes of assessment commonly used with this population include 
neuropsychological testing, neuroimaging, and assessments of capacity and 
activities of daily living. In addition to informing diagnostic decisions, these 
assessment methods can inform treatment directions.  
6.1.3 A recent systematic review identified that certain cognitive deficits (i.e. 
response disinhibition, impaired higher order executive functions [e.g. 
planning, problem solving] and long-term memory failures) are associated with 
a greater risk of relapse in alcohol-dependent individuals and should therefore 
be the targets of cognitive remediation efforts if identified (Rolland et al., 
2018). Similarly, assessments relating to capacity and the ability to undertake 
activities of daily living have clear implications for treatment options.  
 
6.2  Evidence 
 
6.2.1  Neuropsychological assessment 
6.2.1.1  The evidence underpinning a variety of neuropsychological tests used to 
assess ARBD has recently been synthesised and discussed in a large-scale 
systematic review (Heirene, Roderique-Davies, Roberts, & John, 2016; 
Heirene et al., 2018a). The findings relating to cognitive screening instruments 
from this review are discussed in Chapter 5 and therefore this section focuses 
on comprehensive tests of cognition (only a summary of the key findings is 
presented here; see section Appendix C for more details). 
6.2.1.2  Memory: The most useful tests of memory identified by Heirene et al. (2018a) 
were the Rivermead Behavioural Memory Test-3 (RBMT-3; Wilson et al., 




tests offer relatively comprehensive assessments of memory and learning and 
are highly sensitive to alcohol-related memory deficits. 
6.2.1.3 Executive dysfunction: Heirene et al. (2018a) recommended the Behavioural 
Assessment of the Dysexecutive Syndrome (BADS; Wilson, Alderman, 
Burgess, Emslie, & Evans, 1996) as the most useful test for assessing 
executive function in ARBD. The BADS assesses multiple executive skills in 
an ecologically focused format and has demonstrated a high level of sensitivity 
to the cognitive impairments associated with ARBD (Maharasingam et al., 
2013; van Oort & Kessels, 2009).  
6.2.1.4 General intelligence and battery tests: According to Heirene et al. (2018a), 
the intelligence test with the largest evidence base to underpin its use in 
ARBD assessment is the Wechsler Adult Intelligence Scale (WAIS; Wechsler, 
1958), which is often viewed as the gold-standard assessment of intelligence 
(Hayes et al., 2016). Since Heirene and colleagues’ review, a second battery 
test has also been evaluated for ARBD assessment and diagnosis: The 
Repeatable Battery for the Assessment of Neuropsychological Status (R-
BANS). Brown et al. (2018) found an optimum cut-off score of ≤83 produced a 
sensitivity of 89% and specificity of 67% for the R-BANS when comparing 
those with ARBD (including KS) and alcohol dependent individuals without 
ARBD.   
6.2.1.5 Pre-morbid ability: The final area of neuropsychological assessment 
concerns the evaluation of pre-morbid ability. That is, an assessment (or 
estimate) of a person’s cognitive ability prior to the onset of ARBD, thereby 
allowing clinicians to more accurately determine the extent of their impairment. 
The most commonly used and well-validated method for this purpose is the 
National Adult Reading Test-Revised (NART-R; Bright, Hale, Gooch, Myhill, & 
van der Linde, 2016), which assesses a person’s ability to recognise and 
pronounce phonetically irregular words. The test is predicated on the 
assumption that vocabulary is highly correlated with intelligence and relatively 
impervious to most forms of brain damage. 
6.2.1.6 Overall, neuropsychological testing offers an effective and relatively 
inexpensive method of ARBD diagnosis and provides a wealth of information 
regarding each person’s symptomology in a frequently varied condition. 
However, neuropsychological test outcomes alone provide insufficient 
evidence for making ARBD diagnoses due to the multiple possible causes of 
impaired performance on such tests (e.g., head injuries, neurodegenerative 
diseases, poor pre-morbid functioning etc.). As a result, all neuropsychological 
test outcomes need to be considered in conjunction with a clinical diagnostic 




accurate diagnoses.  Repeat testing enables the charting of any trends before 
finalising a diagnosis. 
 
6.2.2.  Neuroimaging 
6.2.2.1 Neuroimaging procedures, including Computed Tomography (CT) and 
Magnetic Resonance Imaging (MRI), are also frequently used in the 
assessment and diagnosis of ARBD alongside, or in place of, 
neuropsychological testing. They provide, safe, non-invasive methods that 
allow for the continual monitoring of a person’s neurological health throughout 
the course of their condition (Zahr, Kaufman, & Harper, 2011). MRI, in 
particular, has been used in research to characterise the neurological damage 
associated with ARBD, demonstrating widespread structural brain changes.  
6.2.2.2 As with neuropsychological measures, the diagnostic capabilities of 
neuroimaging for WKS have also been evaluated. Antunez et al. (1998), found 
the sensitivity of CT imaging for WE was poor, at only 13%. MRI, while 
considerably more sensitive to WE, had a low sensitivity level of 53% and a 
high specificity of 93%. The poor sensitivity of imaging to ARBD was further 
illustrated by Lough (2012), who found 13% of 48 persons with WE had MRI 
results suggestive of a normal brain. Still, although the diagnostic accuracy of 
imaging does not approach the levels found for neuropsychological testing, it 
can be useful in excluding other pathologies (e.g., vascular issues) that could 
provide alternative explanations for the cognitive deficit observed (Beaunieux, 
Eustache, & Pitel, 2015). MRI has also proved useful in detecting 
improvements in brain health in alcohol dependent individuals, including the 
increase in white matter volume often seen following periods of abstinence 
(Gazdzinski, Durazzo, & Meyerhoff, 2005; O'Neill, Cardenas, & Meyerhoff, 
2001).  
6.2.2.3   Existing radiology protocols state that CT scans should be undertaken initially, 
followed by an MRI.  In clinical practice with this patient group, more 
information can be derived from an MRI.  A change in protocols following 
consensus dialogue with Radiology Leads across Wales needs to be achieved 
for ARBD patients in order to save unnecessary radiation of a CT scan for 
these patients. 
6.2.2.4 Despite the many benefits of imaging methods, they (like neuropsychological 
testing) are unable to identify any single sign that can differentiate ARBD from 
other possible pathologies that share similar features (Sechi & Serra, 2007). 
Additionally, the use of imaging may be less accessible than cognitive testing 
in some locations. Nonetheless, they represent a useful method for the 





6.2.3.  Nutritional assessment 
6.2.3.1 The evaluation of nutritional status plays an important role in ARBD 
assessment and can be used to assist diagnostic decision making (Sechi & 
Serra, 2007). Thiamine (vitamin B1) levels, in particular, are the frequent 
subject of nutritional assessments due to the central role played by a 
deficiency of the vitamin in the etiopathogenesis of WKS and, as more recent 
research suggests, all forms of ARBD (Pitel et al., 2011).  Galvin et al. (2010) 
have suggested that the total thiamine in blood should be measured 
immediately before administration of thiamine supplementation, and that the 
method of choice for determining thiamine levels should be high-performance 
liquid chromatography analysis. However, it should be noted that normal or 
even elevated levels of thiamine should not be used as a criterion for the 
exclusion of WE as depletion can be transient (see Lough, 2012). 
6.2.4  Assessment of Activities of Daily Living 
6.2.4.1 In their review of the literature surrounding ARBD assessment, Horton et al. 
(2015) found only one study (Irvine & Mawhinney, 2008) that assessed ADLs 
in those with the condition using the Life Skills Profile (LSP). The LSP is an 
observational scale completed by an informant involved in the care of the 
person and focuses on five areas: self-care ability, social contact, 
communication, responsibility and anti-social behaviour. The scale is 
strengths-based, focusing on what individuals are capable of doing, and may 
therefore provide useful information to inform treatment options and track their 
effects on important indicators of behavioural and social function. The Bristol 
ADL is also a useful tool in capturing the main areas of ADLs. 
6.2.5  Other considerations in ARBD assessment and diagnosis 
6.2.5.1 Assessment of mental capacity is broadly defined as the ability of a person to 
make a decision (see chapter 7). 
6.2.5.2 Research suggests a number of other relevant considerations should be made 
in relation to when assessments are implemented and how outcomes should 
be interpreted. One of the foremost considerations is the point at which 
neuropsychological tests are administered. A review by Walvoort, Wester, and 
Egger (2013) found it requires six weeks of abstinence before reliable 
neuropsychological performance can be achieved.  
6.2.5.3 Repeat testing is also required to monitor cognition over the course of 
treatment. The Royal College of Psychiatrists (2014) have recommend that 
following initial assessments, more detailed cognitive assessments should be 
undertaken after three months, then repeated at six month intervals for three 




effects have on test performance (Horton et al., 2015) and use parallel 
versions of tests if available to minimise such effects. See sections 7 and 8 for 
further information about the stages of assessment.  
6.2.5.4 When interpreting the outcomes from neuropsychological or neuro-radiological 
assessment, it is also important to consider the effects of any potential 
comorbid disorders on neurocognitive health. For example, a variety of 
psychological conditions are known to have delterious effects on cognition, 
including depression (Bosaipo, Foss, Young, & Juruena, 2017), attention 
deficit disorder (Dobson-Patterson, O’Gorman, Chan, & Shum, 2016) and 
schizophrenia (Bora & Pantelis, 2015), warranting a consideration of any co-
existing psychopathology.  
6.2.5.5 The presence of cerbrovasular disease and traumatic brain injuries should 
also be considered during assessment due to their high prevalence (25%) 
within the ARBD population (Wilson et al., 2012).  
6.2.5.6 While neuropsychological testing, neuroimaging and evaluations of nutritional 
status can inform diagnosis, they must be combined with clinical examination 
to make accurate diagnoses and avoid misdiagnosis. Indeed, the most 
efficient method for the early identification of WKS has been said to be careful 
clinical observation, particularly in situations where malnutrition may be 
suspected (Sechi & Serra, 2007). Following clinical suspicion, the diagnostic 
approaches discussed above can be used effectively to confirm or deny the 
diagnosis (Scalzo, Bowden, & Hillbom, 2015).  
6.3 Recommendations  
6.3.1  All alcohol detoxifications should be undertaken in line with NICE clinical 
guidance and as part of a planned care pathway, in conjunction with local 
addiction specialist services and recorded on the patient management system 
within the clinical alcohol services . 
6.3.2  Cognitive screening of individuals with a history of significant alcohol use 
should be routine (on at least a quarterly basis if alcohol consumption 
continues) in clinical and community-based settings to support the 
identification of those with/at risk of ARBD.  Screening and diagnosis of ARBD 
must be undertaken by appropriately trained clinicians.    
6.3.3  Change to the existing Radiology neuroimaging protocol is required, to provide 




7. Pathways for Assessment and Treatment  
7.1 Background 
7.1.1 The variability and the various syndromes within ARBD brings about clinical 
challenges in the areas of recognition, screening, assessment, having 
appropriate treatment pathways in healthcare and non-healthcare settings and 
the longer term rehabilitation needs (depending on the clinical syndromes).   
7.1.2 Whilst dealing with the various syndromes in ARBD, the cognitive impairment 
may have an impact on an individual’s awareness and understanding of their 
circumstances, and equally may have implications for understanding and 
being concordant with the interventions.  This may have legal implications in 
that a comprehensive assessment of the individual’s capacity to make 
decisions and the subsequent use of the Mental Capacity Act 2005 may 
become important. 
7.1.3 The RCP report on ARBD (2014) highlights a paucity of evidence based 
clinical guidelines for the management of ARBD which is reflected in 
organisational and commissioning issues e.g. rarely does a single Mental 
Health speciality take responsibility for this group of patients (Leenane, 1986; 
Price et al, 1988); there is a lack of diagnostic awareness and expertise  within 
psychiatry, medical and nursing staff; few existing pathways of assessment 
and care; stigma and lack of resources. This often results in this patient group 
being “passed from pillar to post”.   
7.1.4 In tackling the problem of ARBD and working through the maze of all 
syndromes with wider diagnostic, treatment, legal, commissioning and funding 
issues, evidence from specialist ARBD services has begun to highlight that 
with clinically validated assessment tools, early identification of ARBD with 
pharmacological, psychosocial interventions and having a rehabilitative model, 




7.2.1 Primary Care 
7.2.1.1 In order to prevent and manage ARBD, use of NICE recommended tools 
becomes crucial right from the first point of contact with the health services.  
To reduce the risk of alcohol related withdrawals and further cognitive 
damage, medically assisted withdrawals should be offered as per the NICE 




“For service users who typically drink over 15 units of alcohol per day and/or 
who score 20 or more on the AUDIT, consider offering an assessment and 
delivery of community based assisted withdrawal or assessment and 
management in specialist alcohol services if there are safety concerns about 
the community based assisted withdrawal.” 
7.2.1.2 In addition to the assessment and management as per NICE guidelines within 
Primary Care, nutritional assessments and vitamin supplementation at an 
early stage is more likely than not to prevent further damage.  Whilst 
intravenous antibiotic related services within Primary Care settings are well 
established in Wales now, the use of parenteral Pabrinex® is still riddled with 
inconsistencies due to concerns over the risks of anaphylaxis.  There is 
sufficient evidence in relation to this, including that provided by The 
Committee on the Safety of Medicines, British Association for 
Psychopharmacology, National Addictions Centre at Kings College, and NICE, 
to highlight that the benefit to risk ratio of anaphylaxis with parenteral thiamine 
favours the use of parenteral thiamine.  Given that intravenous antibiotic 
services are well established, initiation of parenteral thiamine within the 
Primary Care setting should be seriously considered.  
7.2.1.3 The recent Healthcare Inspectorate report (2018) have reflected a lack of 
clinical consistency in recognising and hence assessing and managing alcohol 
related problems within Primary Care in Wales.   
7.2.2 Specialist Substance Misuse Treatment Services 
7.2.2.1 NICE guidelines (2011) recommend that all patients referred to alcohol 
treatment services should have a cognitive assessment.  It is well recognised 
that individuals who present to alcohol services for medically assisted 
withdrawal or detox programmes may have raised blood-alcohol levels and as 
a direct consequence, an effect of alcohol related decline in cognitive 
performance.   
7.2.2.2 Longer term cognitive dysfunction can only be assessed after 60 days of 
abstinence (Oslyn and Kerry, 2003). 
7.2.2.3 Tools such as MoCA or ACE 3-R can be considered earlier on in the medically 
assisted withdrawal programmes for this cognitive assessment (see Chapter 
6).  Patients with a higher risk of developing thiamine deficiency related brain 
damage – high risk drinkers, low BMI, patients missing regular meals and 
those with a long history of alcohol misuse, should be prescribed parenteral 





7.2.2.4 After the detoxification, emphasis on a longer-term treatment plan with regular 
cognitive assessments, maintenance of abstinence, nutritional and 
psychosocial support along with assessment of capacity to engage in 
treatment programmes needs to be considered. 
7.2.2.5 Alongside the pharmacological, nutritional and psychosocial support, a 
number of neuropsychological and cognitive rehabilitative approaches have 
shown to be beneficial and can be considered such as errorless learning, 
assisted technology, enhancing executive functioning, mood modification and 
memory cueing. 
7.2.3 Legal Framework and ARBD – Mental Capacity Act 
7.2.3.1 The interface issues of addiction, ARBD, the Mental Capacity Act, 2005 (MCA) 
and the Mental Health Act 1983 (MHA) are complex.  Whilst addiction per se 
does not fulfil the criteria for the use of the MCA, ARBD as a diagnostic 
syndrome does.  The large majority of people with ARBD of any severity may 
present primarily with cognitive damage which has implications on their 
capacity to understand and engage with the Treatment Programmes.   
7.2.3.2 Whilst the MHA may be used for ARBD, the practical challenges from clinical 
experience and data from Cwm Taf University and Aneurin Bevan University 
Health Boards on the use of the MHA highlights that the MHA is generally not 
used in Wales for ARBD.  However, assessing the capacity of individuals with 
alcohol related problems becomes important in acute hospital settings as well 
as in community settings after having achieved acute physical stabilisation.   
7.2.3.3 MCA facilitates the assessment of the individual’s capacity to make decisions 
and is based on the five principles of:  
 
 Presumption of capacity. 
 Individuals to be supported to make their own decisions. 
 A person is entitled to make an unwise decision Best interest – all 
actions and decisions must be in the person’s best interests. 
 Using least restrictive options. 
 
7.2.3.4 When assessing capacity under the MCA, it is important to understand that 
the assessment of capacity has to be done by the decision maker where the 
decision maker is the person who is deciding whether to take action in 
connection with the care or treatment of an adult who lacks capacity or who is 
contemplating making a decision on their behalf:  
 
 Where the decision involves medical treatment – the doctor proposing the 




 When nursing care is provided, the nurse is the decision maker. 
 For most day-to-day actions or decisions, the decision maker will be the 
person who is most directly involved with the person at the time.  
 Outside hospital, this is most likely to be social workers, care workers and 
family members.  Most people have the capacity to make most decisions 
themselves.  
 
7.2.3.5  When assessing a person’s capacity to make a time and issue-specific 
decision, practitioners should refer to the statutory Code of Practice to the 
MCA which sets our specific guidance on assessing mental capacity, best 
interest decision- making and the role of the IMCA.  
 
7.2.3.6 Further whilst determining capacity, a two-stage test of capacity must be 
followed –  
Diagnostic test- This answers the question “is there an impairment of, or 
disturbance in the functioning of persons mind or brain” followed by a 
functional test which answers the question “is the impairment or disturbance 
sufficient that the person lacks capacity to make that particular decision”.   
Whilst looking at the functional test, four areas need to be fulfilled for a 
person to be deemed to have capacity and these include:  
 The ability to understand the decision 
 The ability to retain information about their decision 
 The ability to use and assess information about the decision  
 The ability to communicate their decision. 
If a person lacks function in any one of these areas, then this represents a 
lack of capacity.   
 
7.2.3.7 When capacity is assessed it is important that it is decision specific. If the 
person lacks capacity in relation to that specific decision a Best Interests 
Decision must consider the individuals wishes and the least restrictive option.   
7.2.3.8 The use of MCA is also relevant in clinical practice when dealing with people 
who express or demonstrate lack of motivation/denial of alcohol problems.  
For most people with alcohol dependence, denial has a psychological basis 
and can be best conceptualised as a defence mechanism. However, in 
individuals with alcohol-related cognitive impairments, denial can have a 
cognitive basis. The latter reflects an issue of capacity and needs to be 







7.2.4 Commissioning of Services 
7.2.4.1 The absence of well-established clinical guidelines, lack of expertise and other 
factors highlighted earlier implicate that commissioning of services for ARBD 
in Wales has not been a priority to date.  
7.2.4.2 Commissioning services for ARBD need to augment the integration of current 
services based on evidence from different service models, summarised in 
Table 3.  
7.2.4.3   Social Services undertake assessments with, and commission care packages 
for, many individuals with ARBD as in some areas they are considered 
ineligible for health funded placements.  This is not reflected in Table 3. 
Table 3 - Commissioning for ARBD- Adapted from CR185 (Royal College of 
Psychiatrists, 2014) 
Service Model Advantages Disadvantages 
Single/dedicated 
service 
- Deliver totality of care 
and rehabilitation 
- Access to a range of 
service provisions 
- Significant experience 
for management of 




services are best 
suited for this model 
- Few Comprehensive 
Neuropsychiatric 
services for ARBD 
- Private organisations 
fill in gap- No 
Standardisation and 
Effectiveness can be 
variable, often ‘out of 
area’ with variable 
costs & lack of 
integration with NHS 








- Specific ARBD 
commissioned 
services within NHS 







- Better integration 
within Health and 
Social Care 
- Time constraints due 
to personalised 
packages 












- Specialists led 
- Increase in expertise 
of the generic team 
- Scope of integration 
with Health and Social 
care 
- Possibly best for low 
prevalence areas 
- No current services 













7.3.1  Establishment of dedicated ARBD Services within each Health Board, with 
ARBD clinical specialist, clinical psychologist, occupational therapist, social 
services and general medicine and timely access to appropriate evidence 
based diagnostic tools.  
7.3.2  Establishment of regional inpatient centres of excellence for ARBD to support 
appropriate diagnostic assessment, research and evaluation on clinical and 
service delivery models. 
7.3.3 Patients with a higher risk of developing thiamine deficiency related brain 
damage – high risk drinkers, low BMI, patients missing regular meals and 
those with a long history of alcohol misuse, should be prescribed parenteral 






8. Treatment and support provision  
8.1 Background 
8.1.1 Few dedicated services currently exist across the UK for the management of 
ARBD and, as a result, patients may be placed within a range of different 
service types such as adult mental health services, memory services and 
alcohol treatment services. Alcohol services may meet some of their needs 
but struggle to engage those with cognitive impairment. Older adult mental 
health services can provide longer term care for those with permanent 
cognitive impairment but many people with ARBD are younger than their 
threshold age (often 65) and these services generally do not have the 
expertise to deal with alcohol misuse (McCabe, 2006) As a result patients can 
find themselves placed between services with disagreement over which 
service should take the lead.  
8.1.2 Where specialist services do exist (both community and residential), it is 
possible to provide tailored cognitive rehabilitation alongside supportive 
alcohol treatment programmes, delivered by staff with knowledge and skills in 
the management of ARBD (Cox et al, 2004). 
8.2 Evidence 
 
8.2.1 The key principles associated with the psychosocial rehabilitation of patients 
with ARBD are: 
 Prioritisation of abstinence. 
 A rehabilitative approach to activities of daily living. 
 Active family engagement. 
 Multidisciplinary management (North et al, 2010). 
 
8.2.2 The five stage model (Wilson et al, 2012) outlined below provides the basis for 
action. With assertive follow-up of patients on the five-stage treatment model, 
relapse into alcohol misuse is 10%, mortality is 10% and there is an observed 
85% reduction in hospital readmission rates. 
Table 4: Five Stage Model of Alcohol Related Brain Damage (Wilson et al, 2012) 
Stage Focus of Treatment Average Duration 
Acute Medical Stage Physical stabilisation and 
withdrawal from alcohol 
Days-weeks 
Acute Global Confusion Psychosocial assessment 2-3 months 
Non-permanent Cognitive 
Dysfunction 
Therapeutic rehabilitation Up to 3 years 








8.2.3 Patients with ARBD tend to present in one of two ways: 
 Acute presentation, often within the general hospital setting, with acute 
confusion arising from alcohol withdrawal and possible intercurrent illness. 
 Chronic presentation in the community with a history of gradual cognitive 
decline. 
 
8.2.4 Patients presenting acutely will often be seen within Stage 1 but those 
presenting in the community may be seen at any stage. In such cases, a 
robust assessment is vital to ensure that interventions are tailored to the 
appropriate stage. Not all individuals will progress through all five stages – 
some will regain near normal cognitive function in Stages 2 or 3; hence it is 
vital to develop flexible care plans that can adapt to potential improvements.  
8.2.1 Acute Medical Stage – Physical Stabilisation and Withdrawal from 
Alcohol 
8.2.1.1  The main focus for this stage is to ensure patient safety, stabilise any 
coexisting medical conditions and appropriately manage alcohol withdrawal in 
line with national guidance (NICE, 2017).  Most cases will be managed within 
the acute hospital setting and the initial priority is the physical health of the 
patient and will often include the use of high dose, parenteral thiamine. Once 
the physical condition has stabilised, a more in-depth assessment should be 
made and would appropriately include past history of alcohol 
consumption/treatment for alcohol related problems, a corroborative history to 
clarify functional evidence of cognitive impairment and confabulation and any 
information that would contribute to care planning and eventual discharge 
(MacRae & Cox, 2003). As part of this process it is important to consider the 
assessment of mental capacity and to develop an appropriate risk 
management plan.  
8.2.1.2  Assessments of cognitive function should form part of the initial assessment of 
all patients with alcohol use disorders and should be repeated as part of the 
ongoing monitoring process of those with ARBD (Royal College of 
Psychiatrists, 2014).  
8.2.1.3  It is important to combine cognitive testing with a clinical diagnostic process 
that includes investigations to rule out alternative or additional intracranial 
pathology (Oslin & Carey, 2003) and a more in-depth 






8.2.2 Acute Global Confusion – Psychosocial Assessment 
8.2.2.1  During this phase improvements will be noticed for a significant proportion 
patients as long as they are able to remain abstinent from alcohol. The rate 
and extent of the improvement will depend upon the levels of underlying brain 
damage as well as any co-occurring physical or mental health problems. 
Some patients can be discharged back to their home environment during this 
stage, but some may require a higher level of support (e.g. residential care, 
supported accommodation).  Abstinence should be prioritised, and 
involvement of specialist alcohol treatment services should occur at an early 
stage, although standard treatment approaches may need to be adapted to 
take account of levels of cognitive impairment (MacRae & Cox, 2003). If the 
patient is unable to make informed decisions about abstinence as a result of 
impairment of memory and decision-making, consideration should be given to 
the use of the MCA to provide appropriate protection.  
8.2.2.2  The Acute Global Confusion stage has five major therapeutic themes: 
 
 Normalisation – to include good nutrition, mood stabilisation, regularisation 
of sleep pattern (Malloy et al, 1990) and strengthening of family 
relationships (Yivisaker & Feeney, 1998; Jacques & Anderson, 2002). 
 Developing a therapeutic relationship – with key members of the care 
team. 
 Orientation – mainly with respect to time but may need orientation for 
place and person. 
 Memory support – strategies to support memory function can be 
introduced at this stage (see below) (Baddeley et al, 2002). 
 Continual assessment – to ensure that the care plan and risk 
management plan remain tailored to the patient’s need as cognitive 
function improves. 
 
8.2.3 Non-permanent Cognitive Dysfunction – Therapeutic Rehabilitation 
8.2.3.1  Some patients will recover significantly during Stage 2 and not progress to 
Stage 3. For those who do, targeted rehabilitation can continue to produce 
improvements in cognitive function for up to three years. This stage should be 
underpinned by robust care planning and a strong relationship with the 
coordinator of care, who should be an experienced clinician with appropriate 
knowledge and skills in relation to ARBD. The care plan should be regularly 
reviewed and adapted to changing needs during this stage and there are a 
number of issues that need to be considered within the care plan: 
 Developing autonomy 




 Orientation and memory support 
 Impulse and behaviour control 
 Managing apathy and motivation 
 Managing alcohol 
 Developing relationships 
 
8.2.3.2  Formal monitoring of progress should continue throughout this phase with 
cognitive testing typically being repeated every six months to ensure that 
interventions remain appropriate to patient need (Royal College of 
Psychiatrists, 2014). 
8.2.3.3  Evidence to support specific cognitive interventions in ARBD is not strong but 
there is support for general treatment approaches (Svanberg & Evans, 2013). 
As has already been stated, all approaches are enhanced by tailoring them to 
the specific needs of the patient and, as such, a comprehensive, flexible care 
plan is vital (Fals-Stewart & Lucente, 1994). 
Orientation and Memory Support 
8.2.3.4  Interventions found to be effective in this stage are derived from descriptive 
research conducted in patients with acquired brain injury as well as ARBD 
(Bates et al, 2002; MacRae & Cox, 2003).  Allowing more time for 
interventions, giving patients greater explanations and encouraging them to 
explain the concepts presented to them, increases subsequent recall 
(VanDamme & d’Ydewalle, 2008). There is also evidence that ‘errorless 
learning’ improves recall (Kessels et al, 2007).  In errorless learning the 
patient is asked to repeat information immediately after it has been presented, 
reducing the amount of ‘guesswork’ which would otherwise simply repeat 
incorrect information. The use of diaries and electronic reminders helps with 
attendance at appointments (Baddeley et al, 2002) and providing structured 
rules improves problem solving abilities (Bardenhagen et al, 2007).  
Supporting Abstinence from Alcohol 
8.2.3.5  Traditionally abstinence from alcohol is supported by both psychosocial and/or 
pharmacological interventions delivered as part of relapse prevention 
programmes (NICE, 2011).   Relapse prevention medication requires informed 
consent before it can be commenced and must be taken regularly. Cognitive 
impairment can affect a patient’s capacity to consent to medication and their 
ability to observe a regular dosing regimen. Standard relapse prevention 
counselling relies on a degree of cognitive flexibility and abstract thinking that 
individuals with ARBD may find difficult. That is not to say that relapse 
prevention strategies cannot be used in patients with ARBD but that standard 




It is important to introduce educational material about the effects of alcohol 
when cognitive function has improved to a suitable level. Even then, 
individuals with cognitive impairment will take longer to benefit from 
interventions and may need more frequent sessions (McCrady & Smith, 1986). 
Presenting information repeatedly in a variety of formats (e.g. written, verbal, 
pictorial) may also help (Royal College of Psychiatrists, 2014). 
Treatment of Co-occurring Conditions 
8.2.3.6  Many patients with alcohol problems present with co-occurring physical and 
mental health disorders. In themselves these can contribute to the apparent 
level of cognitive impairment (e.g. poor motivation in depression, intermittent 
confusion in hepatic impairment). It is important, therefore, to ensure that 
these are treated as part of the overall management of ARBD (Lingford-
Hughes et al, 2012). 
8.2.4 Transition Stage – Adaptive Rehabilitation 
8.2.4.1 Within Stage 3 the patient will ultimately reach their optimum level of recovery 
and, as their improvements plateau, Stage 3 will blend into Stage 4. During 
the transition stage it is important to reassess the patient’s functioning and the 
amount of support they require to live as independently as possible. A full 
occupational therapy assessment is recommended at this stage so that any 
necessary adaptations to the home environment can be made.  
8.2.4.2  Often Stage 4 involves the transfer of the patient from a residential setting to a 
more independent one such as supported living or to a home environment with 
care packages. It is important that such transfers of care are adequately 
planned to ensure that the skills gained in Stage 3 are transferred to the new 
environment and that the new carers can be trained and supervised in 
supporting them. 
8.2.5 Permanent Cognitive Dysfunction – Social Integration and Relapse 
Prevention 
8.2.5.1 The two main therapeutic principles of this stage are to prevent relapse into 
alcohol misuse and to maintain an optimum level of independence and quality 
of life over the long term. The aim is to support the patient to live in the least 
restrictive environment with whatever level of cognitive impairment remains. 
Relapse prevention interventions will need to be tailored to the specific 
abilities and needs of the patient and may require specialist workers to deliver 
them. Structured activities and weekly routines help to promote long term 




8.3  Recommendations 
8.3.1  Establishment of dedicated ARBD Services within each Health Board, with 
ARBD clinical specialist, clinical psychologist, occupational therapist, social 
services and general medicine and timely access to appropriate evidence 
based diagnostic tools.  
8.3.2  Establishment of regional inpatient centres of excellence for ARBD to support 
appropriate diagnostic assessment, research and evaluation on clinical and 




9. Support for ARBD patients who are non-abstinent  
9.1 Background   
9.1.1 The cognitive impairment of ARBD is likely to worsen with continued drinking 
and abstinence is, therefore, the main goal of treatment. However, some 
patients choose to continue to drink and are often automatically excluded from 
services as a result. Guidelines on the management of ARBD tend to assume 
abstinence and there is a lack of guidance on how to manage those unwilling 
or unable to achieve this.  
The decision-making process 
9.1.2  In British law, adults without any impairment of capacity are allowed to make 
their own decisions regarding alcohol consumption, even when these 
decisions might seem unwise to others. Before accepting these decisions, 
however, professionals need to be assured that two factors have been fully 
explored: 
 The patient has received an appropriate assessment of their capacity to 
make that decision. 
 The patient has been given all the information they require, in a form they 
can easily understand, in order to be able to make the decision. 
 
9.1.3 Some patients and health / social care professionals are unaware that ARBD 
can improve with abstinence. This can lead to a misguided attitude of “they 
might as well carry on drinking” which then denies the patient the opportunity 
to improve their condition. Staff working with this patient group need to be fully 
aware of the facts of alcohol related harm so that they can provide patients 
with accurate information, enabling them to make an informed decision.  
9.1.4 The cognitive impairment of ARBD is such that patients may need to be 
presented with this information in a modified way. The use of easy to read, 
engaging patient information leaflets and providing information in short, 
repeated sessions, involving significant others where possible, will improve the 
understanding and retention of information (McCrady & Smith, 1986). If, 
despite such measures, it is clear that the patient cannot use the information 
in order to make a reasoned decision, then the appropriate process under the 
MCA should be followed (see Chapter 7). 
9.1.5 Denial, of varying degrees, is a common accompaniment to alcohol 
dependence and functions as a natural defence mechanism. However, it is 
important to differentiate between this and the inability to retain, process 
and/or weigh up information as a result of brain damage (Rinn et al, 2001).  An 
individual with short term memory problems may make a certain decision 




recall the decision they have made. When assessing the capacity of an 
individual with ARBD to make decisions about continued drinking, it is 
important to assess their recollection of their personal drinking history and its 
related problems, which can influence their understanding of their current 
situation.  
 Those refusing input from services 
9.1.6  Some patients with ARBD who are assessed to have full capacity to make 
decisions about their drinking and who wish to continue to drink, may also 
refuse to engage with alcohol treatment services. Before discharge, the 
following must be considered:  
 Does the individual fully understand what treatment services can offer and 
that a harm reduction approach (as opposed to total abstinence) can be 
supported? 
 Are they being prescribed thiamine supplements?  
 Has safety advice been given to the patient and their carers? 
 Has advice on diet been provided? 
 Has the patient been supported to find appropriate accommodation if 
necessary? 
 
9.1.7  Alcohol Change UK’s Blue Light Manual7 offers practical advice on ways to 
work with drinkers who do not show clear motivation to engage with services, 
and sets out positive strategies that can be used with this client group. The 
manual is available on the charity’s website. 
 Those willing to engage with services 
9.1.8  Some patients with ARBD who choose to continue to drink, may be willing to 
engage with services (both alcohol treatment services and wider support 
services). It is important that services do not exclude patients who are not 
initially focussed on achieving abstinence and are willing to work within a 
framework of harm reduction. Even though patients with ARBD have cognitive 
deficits, it is possible to deliver harm reduction interventions as long as they 
are modified to take into account their specific areas of impairment. This 
underlines the importance of comprehensive assessments of cognitive 
function, with the gold standard being a full neurocognitive assessment. 
Tailoring the approach to the specific pattern of cognitive deficits experienced 
                                                          
7 Alcohol Change UK.  Blue light manual.  Available at: 





can be highly effective in helping the patient understand their condition and 
the implications of continued drinking. 
9.1.9  Stigma still exists in some services towards patients with ARBD. Although they 
experience problems with mental health, cognition and alcohol, the presence 
of each one can be used as an exclusion criterion for them engaging with 
services aimed to address the others (e.g. alcohol treatment services feeling 
that they cannot deliver interventions to patients with cognitive impairment; 
mental health services feeling that they cannot work with patients who are 
drinking) (Rinn et al, 2001). In reality there is a lot that can be achieved 
particularly if the services work together to support the patient and one 
another. In all cases this is assisted by the existence of a comprehensive care 
plan shared by all services and the patient.   
 
9.2 Evidence   
 
9.2.1 Accommodation 
9.2.1.1 Stable accommodation is an important factor in supporting individuals with 
alcohol related impairment. For patients with ARBD, varying levels of 
supportive accommodation may be required for different patients and also for 
the same patient over time (as their condition either deteriorates or improves). 
Comprehensive accommodation provision should include: 
 Support to live independently in the community. 
 Support for carers where patients are living with significant others. 
 Supported living (shared houses or flats). 
 Residential facilities (specialist or general care homes). 
 Nursing homes (specialist or general). 
 
9.2.1.2 Traditionally supported living and residential/nursing facilities require 
abstinence from alcohol as precondition for tenancy. This can lead to 
vulnerable individuals being unable to access safe accommodation because of 
their difficulties controlling their alcohol intake. There is debate amongst some 
professionals as to the effectiveness of promoting complete abstinence within 
a group that find abstinence difficult to attain and, as such, specialist units 
often choose to take a harm reduction approach. 
9.2.1.3 A study conducted by the University of Stirling considered the knowledge and 
attitudes of staff working in residential homes where patients with ARBD were 
accommodated. They found that staff often held inaccurate beliefs around the 
implications of continued drinking for patients with ARBD and that this, in turn, 
influenced abstinence policies within the homes. This study highlighted the 




and continued drinking are made in a person-centred way and not based on 
the beliefs of staff. 
 
9.2.1.4 In Australia, the Wintringham Project is a specialised model of residential care 
where residents are not required to be abstinent and can access a variety of 
treatment options. It arose from the observation that older people with ARBD 
are less likely to see an improvement in cognitive deficits with abstinence 
(Rota-Bartelink & Lipman, 2007). The model has been criticised however 
because of the fine balance between supporting resident autonomy and 
providing adequate levels of protection from ongoing harm. 
9.2.1.5 Research suggests that a significant cohort of patients with ARBD exists 
within the UK homeless population. A Scottish study assessed 266 homeless 
people from three hostels in Glasgow and estimated the prevalence of ARBD 
within that population to be around 21% (Gilchrist & Morrison, 2005).  This is a 
population unlikely to present directly to treatment services, as they tend to 
lack the social and family support networks seen with other patients with 
ARBD.  
9.2.1.6 An assertive outreach approach will help to pick up undiagnosed cases and 
ensure that these patients are provided with all the relevant information they 
require in order to make treatment decisions. It is important that those who 
choose to continue to drink, can access the same support services as patients 
in accommodation. An important part of this support is helping the individual to 
access appropriate accommodation if this is what they choose to do. 
9.2.2 Thiamine supplementation 
9.2.2.1 A discussion of the value of thiamine supplementation in individuals with 
ARBD who achieve abstinence has already been outlined in Chapter 4. 
However, little has been written about the value of thiamine supplementation 
in those who continue to consume alcohol.  
9.2.2.2 A continuous supply of thiamine is required for full brain function and, at 
normal plasma concentrations, thiamine enters the brain via a high affinity, 
carrier mediated process. Under normal circumstances the rate at which 
thiamine crosses into the brain matches the rate of its utilisation within brain 
tissue. As such the brain is very vulnerable to falling blood levels of thiamine 
(Greenwood et al, 1980; Greenwood & Pratt, 1982; Rindi et al, 1980).  Passive 
diffusion across the blood-brain barrier can occur but requires concentrations 
of thiamine probably not achieved by oral administration in malnourished, 
alcohol-dependent patients (Thomson et al, 2002). 
9.2.2.3 A study of abstinent, previously alcohol-dependent subjects suggested that 




group (compared to controls without a history of alcohol dependence with 
similar thiamine blood levels) (Pitel et al, 2011). This finding supports the 
importance of maintaining an adequate circulating level of thiamine in order to 
reduce the risk of developing memory impairments. This then has practical 
implications for the consideration of thiamine prophylaxis in patients 
presenting to treatment services, as distinct from the treatment of established 
WE or prophylaxis during planned alcohol detoxification.  
9.2.2.4 Patients with an established diagnosis of ARBD would clearly meet the criteria 
by virtue of the diagnosis alone, but would generally exhibit other risk factors 
in addition (particularly homeless patients), clearly qualifying them for the use 
of parenteral thiamine during alcohol withdrawal.  
9.2.2.5 Even patients with ARBD who wish to continue drinking may experience 
unplanned episodes of alcohol withdrawal. Some of these will be monitored 
medically (e.g. an emergency admission because of a head injury) whereas 
others will be completely ad hoc (e.g. enforced withdrawal due to poor 
management of finances secondary to dysexecutive syndrome). It can be 
argued, therefore, that individuals with ARBD are at constant risk of the 
development of complicated alcohol withdrawal including WE, which would 
then add to the burden of their cognitive impairment.  
9.2.2.6 Although no formalised trials exist, services have developed the practice of 
providing parenteral courses of thiamine to those with ARBD who continue to 
drink in the community to guard against the additional cognitive burden of 
unplanned withdrawals. These courses are provided alongside an ongoing 
prescription of oral thiamine. Although no formalised human trials have been 
carried out, animal models have shown that the brain damage caused by 
alcohol appears to be more severe in the presence of thiamine deficiency and 
that recurrent periods of thiamine deficiency cause cumulative brain damage 
(Crowe & El-Hadj, 2002; Price et al, 1988; Ciccia & Langlais, 2000).  Some 
authors, therefore, conclude that alcohol dependent patients should be given 
prophylactic thiamine as a matter of course, orally or parenterally, to help 
protect the brain during periods of detoxification or whenever they present to 
medical services (Tomson et al, 2012).  
9.2.3 Physical health 
9.2.3.1 Individuals who have a history of alcohol misuse sufficient to cause brain 
damage, are highly likely to have developed additional organ damage. Alcohol 
can damage virtually every organ system in the body, and it is important that 
alcohol-dependent patients have their physical health reviewed. The cognitive 
impairment of ARBD may mean that patients find it difficult to keep 
appointments and so every effort should be made to help them attend 




9.2.3.2 Dependent drinkers often neglect their nutrition. As a result, they may 
experience other nutritional deficiencies aside from thiamine. A good 
assessment of nutritional status is important as is the use of methods to 
improve food intake such as mealtime prompting.  
9.2.3.3 Ongoing alcohol dependence should not be an exclusion criteria for access to 
health services and supportive care and so it is important that relevant 
services receive education on ARBD to help them understand how the 
cognitive deficits can impact on engagement.   
9.2.4 Mental health 
9.2.4.1 Many patients with ARBD have co-occurring mental health problems and it is 
important to manage this as part of the overall treatment with ARBD (Royal 
College of Psychiatrists, 2014).  
9.2.4.2 In patients who continue to drink, it can be challenging to properly assess and 
treat the underlying mental health problem with community mental health 
services unwilling to assess patients until abstinence has been achieved 
(Lingford-Hughes et al, 2012).  NICE recommend that, in patients’ comorbid 
for alcohol dependence and depression and/or anxiety, the alcohol 
dependence should be treated in the first instance as this can lead to 
significant improvement in the mental health symptoms (NICE, 2011).   
9.2.4.3 The difficulty arises, therefore, in dependent drinkers unwilling/unable to 
consider abstinence who present with lowered mood particularly when 
associated with suicidal ideation/behaviour. These patients tend to present 
frequently to crisis services and the cognitive impairment of ARBD will further 
impact on their ability to engage with treatment services. 
9.2.4.4 Even in patients who continue to drink, if there is a presentation of moderate-
severe depression, it is prudent to complete at least some degree of 
assessment which, at the very least, would comprise an immediate risk 
assessment. It is important that crisis mental health services do not include 
acute intoxication as an exclusion criteria particularly when judged on a 
threshold breath-alcohol limit as, due to the development of tolerance to the 
sedating effects of alcohol, individuals with high breath-alcohol levels can still 
engage in meaningful conversations. The level of cognitive impairment also 
needs to be borne in mind as does potential use of the MHA where 
appropriate.  
9.2.4.5 Psychosis in relation to alcohol dependence tends to be a manifestation of 
complicated withdrawal (e.g. the visual and tactile hallucinations seen in 
delirium tremens). However, there is a recognised psychotic disorder, not 




(typically auditory), perceptual distortions, delusions (often of a persecutory 
nature), psychomotor disturbances and an abnormal affect (World Health 
Organisation, 1992).  Some individuals with ARBD with complex confabulation 
may present as if suffering from delusional beliefs. A full mental health and 
cognitive assessment, including collaborative history and consideration of the 
past history, is vital in distinguishing between these two presentations.  
9.2.5 Further progression 
9.2.5.1 Continued drinking in patients with ARBD is likely to lead to further cognitive 
decline and the patient and their carers should be made aware of this.   Even 
if treatment has been turned down in the past, it should not exclude them from 
accessing care in the future. Patients should be encouraged to return to 
treatment services for reassessment if they are concerned about their 
cognitive function. Carers (both professional and family/friend) need also to be 
aware of the potential for loss of capacity to make decisions and the 
appropriate legal protection that would then need to be put in place. See 
Alcohol Change UK - Alcohol and the brain 
9.3 Recommendations 
9.3.1  Area Planning Boards should consider commissioning assertive outreach 
services for patients with ARBD, particularly those who are homeless. 
9.3.2  Social care services consider a comprehensive accommodation provision, not 




10.    Monitoring, surveillance, evaluation and UK-wide 
collaboration 
10.1  Background 
10.1.1 Monitoring the prevalence of ARBD in the UK has been highlighted as a key 
challenge facing health and social care systems due to the absence of a clear 
system for capturing, sharing and aggregating case data (Boughy, 2007; 
Wilson et al., 2012).  
10.1.2 In Wales, a recent investigation found that health and social care 
professionals reported a poor level of inter-service communication regarding 
individuals with ARBD and that support services typically obtained case 
information from referral reports that provided little information about the 
person’s condition or the origin of their diagnosis (Heirene et al., 2018).  
10.1.3 This and previous evidence (e.g., Boughy, 2007) also highlighted a general 
lack of consensus between services as to who should assume responsibility 
for those with the condition, with patients frequently being “passed from pillar 
to post” (Heirene et al., 2018).  
 
10.2  Evidence 
 
10.2.1.  Monitoring and surveillance 
10.2.1.1 Monitoring of ARBD cases in Wales is currently achieved through recording 
hospital admissions using ARBD-related International Classification of 
Diseases-10/ 111 (ICD; World Health Organisation, 1992/ 2018) codes and 
through Specialist Substance Misuse Service patient management data 
systems. The latter, however, while useful for documenting and sharing 
detailed patient information, does not provide a suitable avenue through which 
ARBD case data can easily be aggregated to inform the understanding of the 
incidence and prevalence of the condition.  
10.2.1.2 Hospital admissions data are more suited to establishing prevalence and 
incidence and has been utilised to summarise ARBD-related hospital 
attendance in Wales between 2008 and 2012 (Emmerson and Smith, 2010). 
Figure 2 below displays updated admissions for ARBD in Wales from 2013/14 
to 2019/20.   
10.2.1.3 Over the seven year period there has been an 18.9% increase in the number 
of patients diagnosed with ARBD with a corresponding 41.6% increase in 
hospital admissions, from 387 admissions in 2013-14 to 548 in 2019-20.   It is 




improvements in diagnosis over this time may account for the increase.   In 
2019-20, the ratio of male to female patients is approximately 2:1.   
 
Source: Patient Episode Database Wales, National Welsh Informatics Service (2020) 
 
Figure 2:  Hospital admissions and unique patients admitted with diagnosis of 
ARBD in Wales 2013-14 to 2019-20.  
 
10.2.1.4 The age profile of patients diagnosed with alcohol related brain damage 
(broad definition) is shown in Figure 3.  In 2019-20, there were a total of 321 
individuals hospitalised with a diagnosis of ARBD.  The age group with the 
highest number of diagnoses was 70-74 years, followed by those in the 60-69 
age categories.  Over the last seven years since 2013-14, 17.3% of ARBD 






Source: Patient Episode Database Wales, National Welsh Informatics Service (2020) 
 
Figure 3:  Unique patients admitted with diagnosis of ARBD in Wales 2013-14 to 
2019-20. 
 
10.2.1.5 The number of patients diagnosed with ARBD by health board area of 
residence over the seven year period 2013-14 to 2019-20 is shown in Figure 
4.  The highest numbers of patients admitted for ARBD are recorded in 
Aneurin Bevan and Betsi Cadwaladr University Health Boards.  
 
 
Source: Patient Episode Database Wales, National Welsh Informatics Service (2019). 
 
Figure 4:  Unique patients admitted with diagnosis of ARBD by Health Board area 
of residence in Wales 2013-14 to 2019-20. 
10.2.1.6 There is considerable evidence of a relationship between substance misuse 
including problematic alcohol use and deprivation. The Welsh Government 
produces an index of multiple deprivation which ranks every lower super 
output area (LSOA, small geographical areas with stable populations of about 
1,500) on measures of deprivation. These measures allow every address in 
2013/14 2014/15 2015/16 2016/17 2017/18 2018/19 2019/20
Under 35 6 2 7 3 2 6 3
35-39 8 3 13 9 6 7 2
40-44 18 19 12 11 12 14 15
45-49 19 23 25 23 36 28 28
50-54 39 28 33 35 38 33 30
55-59 30 30 27 41 56 51 39
60-64 43 42 42 47 37 42 46
65-69 49 45 53 46 54 37 48
70-74 24 25 30 39 46 41 58
75-79 15 25 16 38 30 24 36
Over 80 19 15 15 19 23 24 16




Wales to be allocated to a quintile of deprivation and ranked from 20% most to 
20% least deprived. Hospital admission data includes details of these 
quintiles8. Figure 5 shows the number of all patients resident in Wales with an 
ARBD diagnosis and admitted to hospital by each deprivation quintile.  As 
indicated, there is evidence of a relationship, with twice the number of ARBD 
patients resident in the highest deprivation quintile compared with the number 
of those resident in the least deprived quintile.   
 
Source: Patient Episode Database Wales and Welsh Index of Multiple Deprivation, 
National Welsh Informatics Service (2020) 
 
Figure 5:  Number of all individuals resident in Wales admitted to hospital and 
receiving ARBD diagnosis in any position by deprivation quintile in Wales 2013-
14 to 2019-20. 
10.1.2.7  Although easily aggregated, there are considerable limitations to the use of 
hospital admissions data for ARBD monitoring. Anecdotal reports from Welsh 
clinicians suggest that the ICD codes used to label ARBD-related admissions 
are rarely applied, particularly when ARBD is not the primary reason for 
admission (Heirene et al., 2018). These reports are corroborated by Wilson 
and colleagues (2012), who noted that individuals with ARBD are unlikely to 
                                                          
8  Note that deprivation is a measure of the area in which an individual lives, rather than 




be officially diagnosed or have their condition reported in acute hospital 
records. 
10.1.2.8 In addition, it has been suggested that hospital staff may be poor at detecting 
ARBD due to the absence of validated risk assessment tools (Thomson et 
al., 2012). Thus, the true number of hospital admissions of those with ARBD 
is likely to be considerably greater than hospital data would suggest.  
10.1.2.9  The issue is further compounded by the confusion surrounding ARBD 
diagnoses (Emmerson & Smith, 2015) and the lack of a specific “ARBD” 
diagnosis within the ICD, leaving clinicians to choose between the codes for 
alcohol-amnestic disorder/ KS or alcohol-related dementia, despite the 
recent impetus for a move towards using ARBD as a diagnostic term in UK 
clinical practice (e.g., Wilson et al., 2012). 
10.1.2.10  More comprehensive monitoring systems will likely require the consolidation 
of hospital and community-based records from a variety of settings. The 
multifarious and complex needs of this population can mean they first 
present to a variety of different services, including community mental health 
teams, prisons, social services, GP surgeries, community-based recovery 
organisations and homeless hostels (Royal College of Psychiatrists, 2014).  
10.1.2.11 Close monitoring of homeless populations may be particularly important 
given the high prevalence of substance misuse and ARBD within this 
population. Gilchrist and Morrison (2005) found 21% of 266 homeless 
individuals in Glasgow met the criteria for ARBD (compared with estimated 
whole population prevalence rates of 0-2.8% for WKS; Ridley & Draper, 
2015), demonstrating the disproportional risk in this population.  
10.2.2.  Evaluation of specialist service provision 
10.2.2.1  Systematic evaluations of ARBD services in Wales are absent, likely due to 
the limited number of such services and the relative infancy of those in 
existence. Nonetheless, in South Wales, service evaluations of Gwent 
Specialist Substance Misuses Service’s ARBD Clinic and Brynawel 
Rehabilitation Service have been undertaken.   
10.2.2.2  Brynawel Rehab is a provider of residential treatment for drug and alcohol 
dependencies, located in Rhondda Cynon Taf. In 2014 a task and finish 
group was established after social workers in the RCT area had identified a 
need for local services for patients with ARBD. From this, in 2015, a pilot 
study of residential cognitive rehabilitation was established at Brynawel, 
based on six patients over a six month period. Quantitative and qualitative 
data was recorded for the six pilot patients and, although the sample size 




modest improvement in cognitive functioning, noticeable changes in social 
abilities and improved quality of life.  The evaluation period of six months is 
shorter than the three year potential window for improvement noted by 
Wilson et al 2015).   The cognitive rehabilitation programme is now an 
established part of the treatment options available at Brynawel Rehab. 
  Gwent Specialist Substance Misuse Service (GSSMS) ARBD Clinic 
10.2.2.3  GSSMS is the statutory provider of complex needs drug and alcohol 
treatment in the Aneurin Bevan University Health Board area. In 2014 
established a dedicated medical clinic for assessment and diagnosis of 
ARBD and, with time, further support and management options were 
developed. The clinic currently provides: 
• Assessment and diagnosis (including full physical and mental health 
assessments) 
• Ward liaison assessments and advice (to both mental health and physical 
health wards) 
• Inpatient alcohol detoxification 
• Follow-up to monitor changes in cognitive function 
• Psychosocial interventions modified to take account of cognitive impairment 
(a specific workbook was developed) 
• Low key cognitive rehabilitation (utilising the Brain Injury Workbook) 
• Advice to carers (on use of cognitive aids, legal matters etc) 
• Ability to work within legislation (Mental Capacity Act, 2005 and the Mental 
Health Act 1983) where necessary 
 
   An evaluation of the service was performed in 2017. At the time of the 
evaluation, 62 patients had been referred to the clinic and there was sufficient 
data on 22 cases to assess changes to cognitive function, alcohol 
consumption and hospital readmission rates. Over the time of their 
involvement with the clinic, the sample showed significant increases in 
cognitive function (as measured using the ACE-III) and significant decreases 
in alcohol consumption (taking data from Treatment Outcome Profile (TOPS) 
forms). Hospital readmission rates showed little change over the course of 
treatment, but it was noted that the cohort were not frequent attenders initially. 
   The clinic was established without additional funding and so is limited in its 
ability to expand. However, even with this minimal investment of resources, 
significant improvements have been seen. 
10.2.2.4 In North Wales, a general exploration of ARBD has been conducted based on 
data captured from those with the condition in Carenza Care, a service 
specifically for those with the condition (Boughy, 2007) but which has since 




their families describing the positive aspects of the service and about the 
condition in general, but provides little direct evaluation of the interventions 
received in terms of improved outcomes.  The Arbennig Unit, Potens is a 
registered Residential assessment & rehabilitation unit, providing 
accommodation & support for twenty one people with Korsakoffs Syndrome 
(alcohol related brain damage). No systematic evaluation of these services 
has been undertaken.  
10.2.2.5 Outside of Wales, a number of other naturalistic investigations have explored 
the efficacy of services – both ARBD specific and non-specific – for supporting 
and treating those with ARBD: 
 Irvine and Mawhinney (2008) investigated the effects of a supported 
housing project in Northern Ireland for four persons with ARBD, finding 
variable levels of improvement in mental and physical health and 
engagement with family; while the ability to complete activities of daily living 
decreased or remained the same.  
 Wilson et al. (2012) have also published a summary of the outcomes from 
their community-based psycho-social rehabilitation programme for ARBD in 
Liverpool, again reporting improvements in several outcomes – most 
notably an 85% reduction in hospital bed use.  
 More broadly, the Mental Welfare Commission for Scotland (MWCS; 2010) 
met with several individuals with ARBD (and the staff surrounding them) in 
hospitals, care homes and community settings to explore the efficacy of the 
care they were receiving. The report of findings highlighted positive 
improvements in some of the group’s symptoms as a result of the 
interventions they had received; though also highlighted a number of 
concerns including: the lack of appropriate therapeutic and leisure activities 
for this group in services, the absence of treatment goals in many cases, 
and the dearth of specialised training available for staff (MWCS, 2010). 
10.2.3.  UK-wide collaboration 
10.2.3.1  UK-wide collaboration regarding ARBD is currently scant, leaving open the 
opportunity for significant development in this area. Greater collaboration 
across the UK is required to improve identification, diagnosis, treatment and 
care. Indeed, Thomson and colleagues argued in 2012 that a single risk 
assessment tool and clear treatment guidelines should be adopted in the UK; 





10.3.1 Support a comprehensive and co-ordinated programme of evaluation including 
validation of ARBD screening and diagnostic tools, rehabilitative models of 
care, integrated care pathways and community support services 
10.3.2  Support prevalence and incidence studies evidencing the nature and scale of 
ARBD and at risk populations within Wales, including within Prison services to 
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Appendix A - ARBD diagnostic criteria 
 
Introduction:  
The diagnostic criteria for Wernicke’s Korsakoff’s Syndrome (WKS), Alcohol-Related 
Dementia and ARBD are presented below. While the distinctions between WKS, ARD 
and ARBD diagnoses have been debated due to their overlapping symptomology and 
the heterogeneity within these groups (Zhar et al., 2011; Bowden, 1990), the diagnostic 
distinction still offers some merit for clinicians in understanding how classic Wernicke’s 
and Korsakoff’s Syndrome presentations might differ from the criteria proposed for ARD 
and ARBD. It is important to note, however, that the criteria for ARBD proposed by 
Wilson (2013) are yet to be empirically validated. Nonetheless, they provide a 
pragmatic and inclusive approach to diagnosing alcohol-related neurocognitive 
impairment that appears well-used in current clinical practice  
Wernicke-Korsakoff Syndrome: International Classification of Diseases-11 (2018) 
– (Code: 5B5A.1) 
“Description: A thiamine-deficiency syndrome characterized by symmetric hyperaemic 
lesions of the brainstem, hypothalamus, thalamus, and mammillary bodies with glial 
proliferation, capillary dilatation, and perivascular haemorrhage. The syndrome is 
manifested by a confusional state, disorientation, ophthalmoplegia, nystagmus, 
diplopia, and ataxia (Wernicke encephalopathy), with severe loss of memory for recent 
events and confabulation (the invention of accounts of events to cover the loss of 
memory) (Korsakov psychosis) occurring following recovery. Defective binding of 
thiamine diphosphate by transketolase has been found. It appears that the disorder is of 
autosomal recessive inheritance but is expressed as clinical disease only in the event of 
thiamine deficiency.” 
Reference: World Health Organisation (2018). International Classification of Diseases-
11 for Mortality and Morbidity Statistics (online draft). Retrieved from: 
https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/2017611840  
Dementia due to use of alcohol: International Classification of Diseases-11 (2018) 
– (Code: 6D84.0) 
“Description: Dementia due to use of alcohol is characterized by the development of 
persistent cognitive impairments (e.g., memory problems, language impairment, and an 
inability to perform complex motor tasks) that meet the definitional requirements of 
Dementia that are judged to be a direct consequence of alcohol use and that persist 
beyond the usual duration of alcohol intoxication or acute withdrawal. The intensity and 




The cognitive impairment is not better accounted for by a disorder or disease that is not 
induced by alcohol such as a dementia due to another disorder or disease classified 
elsewhere.” 
Reference: World Health Organisation (2018). International Classification of Diseases-
11 for Mortality and Morbidity Statistics (online draft). Retrieved from: 
https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1619582852 
Alcohol-Related Brain Damage: Wilson (2013)   
“A. Criteria for the clinical diagnosis of probable ARBD include the following: 
Evidence of cognitive impairment (as demonstrated by clinical examination or use of 
appropriate instruments) 
Significant history of alcohol use as defined by the minimum average of 35 standard 
drinks per week for men and 28 for women for a period of greater than 5 years. The 
period of significant alcohol use must occur within three years of the onset of cognitive 
deficits. 
B. The diagnosis of ARBD is supported by the presence of the following: 
Alcohol related hepatic, pancreatic, gastrointestinal, cardiovascular or renal disease or 
other end organ damage 
Ataxia or peripheral polyneuropathy (not attributable to other non-alcohol related 
causes) 
Neuroimaging evidence of cerebellar atrophy, especially of the vermis 
Cognitive damage and evidenced ventricular or sulcal dilatation are likely to improve 
within the first 60 days, residual damage will be slower to improve.  
C. The following clinical presentation indicates that there may be complicating 
conditions such as vascular or traumatic lesions: 
The presence of language impairment, especially dysnomia or anomia 
The presence of focal neurological signs or symptoms (except ataxia or peripheral 
sensory polyneuropathy)  
Neuroimaging evidence of cortical or subcortical infarction, subdural haematoma or 
other focal brain pathology 
Elevated Hachinski Ischemia scale score” 
Reference: Wilson, K. (2013). Alcohol-related brain damage in the 21st century. 




Alcohol-induced major neurocognitive disorder (amnestic and non-amnestic 
types): Diagnostic Statistical Manual-5 (2013)  
“Diagnostic criteria for ‘substance/ medication-induced mild or major neurocognitive 
disorder’: 
A) The criteria are met for major or mild neurocognitive disorder (NCD; see next 
page for criteria) 
B) The neurocognitive impairments do not occur exclusively during the course 
of a delirium and persist beyond the usual duration of intoxication and acute 
withdrawal. 
C) The involved substances or medication and duration and extent of use are 
capable of producing the neurocognitive impairment 
D) The temporal course of the neurocognitive deficits is consistent with the 
timing of substance or medication use and abstinence (e.g., the deficits remain 
stable or improve after a period of abstinence). 
Diagnostic features relating to alcohol-induced Neurocognitive disorder (NCD): 
Substance/ medication-induced major or mild NCD is characterized by neurocognitive 
impairments that persist beyond the usual duration of intoxication and acute withdrawal 
(Criterion B). Initially, these manifestations can reflect slow recovery of brain functions 
from a period of prolonged substance use, and improvements in neurocognitive as well 
as brain imaging indicators may be seen over many months. If the disorder continues 
for an extended period, persistent should be specified. 
NCD induced by alcohol frequently manifests with a combination of impairments in 
executive-function and memory and learning domains. The temporal cause of the 
substance-induced NCD must be consistent with that of the use of a given substance 
(Criterion D). In alcohol-induced amnestic confabulatory (Korsakoff’s) NCD, the features 
include prominent amnesia (severe difficulty learning new information with rapid 
forgetting) and a tendency to confabulate. These manifestations may co-occur with 
signs of thiamine encephalopathy (Wernicke’s encephalopathy) with associated 
features such as nystagmus and ataxia. Ophthalmoplegia of Wernicke’s 
encephalopathy is typically characterized by a lateral gaze paralysis.” 
Reference: American Psychiatric Association. (2013). Diagnostic and statistical manual 




Appendix B – Provision of Pabrinex® - British National Formulary 
 
Treatment of Wernicke's encephalopathy, by intravenous infusion of I/V High Potency, 
2–3 pairs 3 times daily for 2 days; if no response, discontinue; if symptoms respond 
after 2 days, given by intravenous infusion of I/V High Potency or by deep intramuscular 
injection into the gluteal muscle of IM High Potency, 1 pair once daily for 5 days or for 
as long as improvement continues.” “Prophylaxis of Wernicke's encephalopathy in 
alcohol dependence, by intravenous infusion of I/V High Potency or by deep 
intramuscular injection into the gluteal muscle of I/M High Potency, 1 pair once daily for 
at least 3–5 days.” Ampoule 1 of 5ml Pabrinex® contains 250mg thiamine 
hydrochloride. BNF guidelines for the treatment of Wernicke’s encephalopathy is two to 
three pairs of IV Pabrinex® each day for two days (2,000mg to 3,000mg thiamine 
hydrochloride per day). For prophylaxis it is one pair IM Pabrinex® each day for five 
days (500mg thiamine hydrochloride per day). Pabrinex® is comprised of two ampules. 
Ampoule one contains thiamine hydrochloride, riboflavin and pyridoxine hydrochloride 
and will not be administered. Ampoule two contains ascorbic acid, nicotinamide and 
anhydrous glucose. 
The most consistent and prominent of these changes include an increase in 
cerebrospinal fluid volume, widespread grey matter volume decreases (particularly in 
the frontal lobes), and reductions in the volume of the corpus callosum, cerebellum, 
pons, mamillary bodies, hippocampus and thalamus (Harper, 2009; Zahr et al., 2011). 
Most of these structural changes are thought to occur along a spectrum, with KS at the 




Appendix C – Neuropsychological assessments 
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Tests: ACE-III = Addenbrooke’s Cognitive Examination-3; BEARNI = Brief Examination of 
Alcohol-Related Neuropsychological Impairments; MMSE = Mini-Mental Status 
Examination; MoCA = Montreal Cognitive Assessment; TEDCA = Test of Detection of 
Cognitive Impairment in Alcoholism. 
Samples: ALs = alcohol-dependent persons with no diagnosed cognitive impairment; ARBD = 





Table 6 displays the average ACE-III performance by alcoholic-dependent individuals 
with and without ARBD as the ACE is the most commonly used test in South Wales to 
assess ARBD (Heirene et al., 2018b) 
 
Domains of neuropsychological assessment (further details) 
Memory is one of the most impaired cognitive domains in ARBD (see Appendix XX), 
warranting further assessment following initial screening to better characterise the 
memory disorder. The most useful tests of memory identified by Heirene et al. (2018a) 
were the Rivermead Behavioral Memory Test (RBMT; Wilson et al., 1989) and the 
California Verbal Learning Test (CVLT; Delis et al., 1987). The RBMT was designed as 
an ecologically focused memory test, offering clinically and practically useful information 
about a person’s memory deficit. The CLVT is a more detailed verbal memory 
assessment that provides a wealth of information regarding memory function that could 
inform treatment approaches. 
Executive dysfunction has also been reported in those with ARBD, with specific 
executive skills differentially affected (Maharasingam, Macniven, & Mason, 2013). 
Based on the available evidence, Heirene et al. (2018a) recommended the Behavioural 
Assessment of the Dysexecutive Syndrome (BADS; Wilson, Alderman, Burgess, 
Emslie, & Evans, 1996) as the most useful test for assessing executive function in 
ARBD. The BADS assesses multiple executive skills in an ecologically focused format 
Table 6.   ACE-III performance by alcoholic-dependent individuals with and 
without ARBD 
 Index (maximum 
score) 
Mean (SD) 







Total score (100) 89.4 (8.9) 78.5 (10.3) 
Attention (18) 17.1 (1.2) 15 (3) 
Memory (26) 21.3 (4) 16.2 (4.6) 
Fluency (14) 12 (2.3) 9.8 (2.6) 
Language (26) 24.3 (2.9) 23.5 (1.6) 
Visuospatial (16) 14.7 (1.3) 14.1 (1.8) 
Note: these test scores should be used as a guide only as the cognitive profile of 
those with ARBD frequently varies and can be influenced by a variety of 




and has demonstrated a high level of sensitivity to the cognitive impairments associated 
with ARBD (Maharasingam et al., 2013; van Oort & Kessels, 2009).  
Heirene and colleagues (2018a) observed that those with ARBD also display deficits on 
subtests of intelligence batteries – namely those involving the assessment of 
processing speed, executive functions and working memory. The intelligence test with 
the largest evidence base to underpin its use in ARBD assessment is the Wechsler 
Adult Intelligence Scale (WAIS; Wechsler, 1958), which is often viewed as the gold-
standard assessment of intelligence (Hayes et al., 2016). Since Heirene and 
colleagues’ review, a second battery test has also been evaluated for ARBD 
assessment and diagnosis: the Repeatable Battery for the Assessment of 
Neuropsychological Status (R-BANS). Brown et al. (2019) found an optimum cut-off 
score of ≤83 produced a sensitivity of 89% and specificity of 67% for the R-BANS when 
comparing those with ARBD (including KS) and alcoholics without ARBD. The 
diagnostic capabilities of the R-BANS were superior to those of the ACE-III in these 
populations, although not significantly so.  
The final area of neuropsychological assessment concerns the evaluation of pre-
morbid ability. That is, an assessment (or estimate) of a person’s cognitive ability prior 
to the onset of ARBD, thereby allowing clinicians to more accurately determine the 
extent of their impairment. The most commonly used and well-validated method for this 
purpose is the National Adult Reading Test-Revised (NART-R; Bright, Hale, Gooch, 
Myhill, & van der Linde, 2016), which assesses a person’s ability to recognise and 
pronounce phonetically irregular word. The test is predicated on the assumption that 
vocabulary is highly correlated with intelligence and relatively impervious to most forms 
of brain damage. 
 
 
